

1 **Niche-specific genome degradation and convergent evolution shaping**

2 ***Staphylococcus aureus* adaptation during severe infections**

3

4 Stefano G. Giulieri^{a,b,c}, Romain Guérillot^a, Sebastian Duchene^a, Abderrahman

5 Hachani^a, Diane Daniel^{a,d}, Torsten Seemann^d, Joshua S. Davis^{e,f}, Steve Y.C. Tong^{f,g},

6 Bernadette Young^h, Daniel J. Wilsonⁱ, Timothy P. Stinear^{a*}, Benjamin P.

7 Howden^{a,b,d*}

8

9 ^a *Department of Microbiology and Immunology, The University of Melbourne at the*

10 *Doherty Institute for Infection and Immunity, Melbourne, Australia*

11 ^b *Department of Infectious Diseases, Austin Health, Heidelberg, Australia*

12 ^c *Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne,*

13 *Australia*

14 ^d *Microbiological Diagnostic Unit Public Health Laboratory, The University of*

15 *Melbourne at the Doherty Institute for Infection and Immunity, Melbourne, Australia*

16 ^e *Department of Infectious Diseases, John Hunter Hospital, Newcastle, New South*

17 *Wales, Australia*

18 ^f *Menzies School of Health Research, Charles Darwin University,*

19 *Casuarina, Northern Territory, Australia*

20 ^g *Victorian Infectious Disease Service, Royal Melbourne Hospital, and University of*

21 *Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne,*

22 *Victoria, Australia*

23 ^h *Nuffield Department of medicine, Oxford*

24 ⁱ *Big Data Institute, Nuffield Department of Population Health, Li Ka Shing Centre for*

25 *Health Information and Discovery, Old Road Campus, University of Oxford, Oxford*

26 OX3 7LF, UK

27

28 *Joint Senior author

29 #Address correspondence to Benjamin P. Howden, bhowden@unimelb.edu.au

30

31 Keywords: within-host evolution, adaptation, *Staphylococcus aureus*, genomics

32

33 **ABSTRACT**

34 During severe infections, *Staphylococcus aureus* moves from its colonising sites to
35 blood and tissues, and is exposed to new selective pressures, thus potentially driving
36 adaptive evolution. Previous studies have shown the key role of the *agr* locus in *S.*
37 *aureus* pathoadaptation, however a more comprehensive characterisation of genetic
38 signatures of bacterial adaptation may enable prediction of clinical outcomes and
39 reveal new targets for treatment and prevention of these infections. Here, we
40 measured adaptation using within-host evolution analysis of 2,590 *S. aureus*
41 genomes from 396 independent episodes of infection. By capturing a comprehensive
42 repertoire of single-nucleotide and structural genome variations, we found evidence
43 of a distinctive evolutionary pattern within the infecting populations compared to
44 colonising bacteria. These invasive strains had up to 20-fold enrichments for genome
45 degradation signatures and displayed significantly convergent mutations in a
46 distinctive set of genes, linked to antibiotic response and pathogenesis. In addition to
47 *agr*-mediated adaptation we identified non-canonical, genome-wide significant loci
48 including *sucA-sucB* and *stp1*. The prevalence of adaptive changes increased with
49 infection extent, emphasising the clinical significance of these signatures. These

50 findings provide a high-resolution picture of the molecular changes when *S. aureus*
51 transitions from colonisation to severe infection and may inform correlation of
52 infection outcomes with adaptation signatures.

53

54 **INTRODUCTION**

55 While *Staphylococcus aureus* is one of the most important human pathogens (1), its
56 common interaction with the human host is colonisation, usually of the anterior nares
57 (2). Comparatively, severe, life-threatening infections such as bacteraemia or
58 osteomyelitis occur very rarely. This suggests that at the macro-evolutionary level
59 *S. aureus* is primarily adapted to its natural ecological niche (the nasal cavity) and
60 to specific selective pressures arising in this environment, such as competition with
61 the resident microbiota (3). By contrast, during invasive infection, a new fitness
62 trade-off needs to be achieved to adjust to environmental challenges that include
63 innate and acquired immune responses (4), high-dose antibiotics (5) and nutrient
64 starvation (6). These trade-offs could occur across three potentially distinctive
65 dynamics of micro-evolution during colonisation and infection (within the colonising
66 population, from colonising to invasive and within the invasive population), leading to
67 nose-adapted, early infection-adapted and late infection-adapted strains. Identifying
68 infection-adapted strains might assist precision medicine strategies for infection
69 prevention and management, and refine the understanding of *S. aureus*
70 pathogenesis versatility, as mutational footprints of selection mirror functions that are
71 critically important for bacterial survival during invasion.

72

73 Emerging genomic approaches for analysis of within-host evolution are among the
74 most powerful means to study bacterial host adaptation (7-9). Studies have shown

75 the remarkable diversity and evolution of colonising populations of *Streptococcus*
76 *pneumoniae* (10) and *S. aureus* (11). In *S. aureus* and *Enterococcus faecium* it has
77 been shown that transition from colonisation to invasion favours strains with specific
78 adaptive signatures (12, 13), while evidence of niche adaptation was noted in a
79 within-host study of bacterial meningitis due to *S. pneumoniae* (14). Further,
80 phenotypic and genomic adaptation (often in response to antibiotic pressure) has
81 been investigated during selected episodes of persistent invasive infections due to *S.*
82 *aureus* (15-17), *Pseudomonas aeruginosa* (18), *Salmonella enterica* (19), and
83 *Mycobacterium tuberculosis* (20). To increase power, bacterial within-host evolution
84 studies have leveraged on large collections of paired samples coupled with statistical
85 models of genome-wide mutation rates (7, 14, 21) and extended the analysis to
86 include chromosomal structural variation (17, 22, 23) as well as intergenic mutations
87 (22, 24).

88
89 Convergent evolution among separated (independent) episode of colonisation or
90 infection is a key indication of adaptation in evolution analyses. However, with the
91 notable exception of one study of cystic fibrosis (25), the convergence has generally
92 been weak in within-host studies of *S. aureus* infections, with no convergence at all
93 (17) or significant enrichment limited to the *S. aureus* master regulator *agr* (12). We
94 hypothesised that in addition to the small sample size, the extended range of
95 bacterial functions potentially under selective pressure (each function being
96 potentially targeted by diverse patho-adaptive mutations) has hampered the
97 identification of important adaptation mechanisms. To overcome the limitations of
98 studies to date, we have pooled all publicly available *S. aureus* within-host evolution
99 studies, and complemented this with a new dataset from a recent *S. aureus* clinical

100 trial (26), in a single large-scale analysis. Rather than focussing on point mutations
101 and small insertions/deletions alone, we leveraged multiple layers of genome
102 annotation (encompassing coding regions, operons, intergenic regions and
103 functional categories) and included chromosome structural variants to compile a
104 comprehensive catalogue of bacterial genetic variation arising during host infection.
105 This strategy enabled the detection of convergent adaptation patterns at an
106 unprecedented resolution. We also outline distinctive signatures of adaptation during
107 colonisation, upon transition from colonisation to infection and during invasive
108 infection.

109 **RESULTS**

110 **The *S. aureus* within-host evolution analysis framework.**

111 We compiled a collection of 2,251 *S. aureus* genomes from 267 independent
112 episodes of colonisation and/or infection, reported in 24 genomic studies (12, 17, 23,
113 27-47) (Table S1). We supplemented this dataset of publicly available sequences
114 with unpublished sequences from 603 serial invasive isolates collected within the
115 CAMERA-2 trial (26).

116

117 After excluding sequences failing quality control and genetically unrelated strains
118 within the same episode, 2,590 genomes (1,397 invasive, 1,193 colonising) from 396
119 episodes were included in our within-host evolution analysis (Figure 1, Table 1,
120 Supplementary files 1 and 2). The most prevalent lineages in the collection were
121 sequence type (ST) 30 (342 strains, 13%), ST 22 (277 strains, 11%) and ST 5 (271
122 strains, 11%); 1001 strains (39%) were *mecA* positive. The collection was
123 representative of the global *S. aureus* diversity, with an even distribution of
124 colonising and invasive strains across the major clades (Figure 2A). The most

125 frequent infection syndrome was bacteraemia without focus (152 episodes, 38.4%),
126 while nasal carriage (166 episodes, 42%) was the most prevalent colonisation
127 condition (Table 1).

128

129

130 Our within-host evolution analysis strategy identified 4,556 genetic variants (median
131 3 per episode, range 0-237) (Supplementary file 3). Importantly, by investigating both
132 point mutations and structural variation, we were able to uncover 214 large deletions
133 (\geq 500 bp), 160 new insertion sequences (IS) insertions and 609 copy number
134 variants, underscoring the role of large chromosome structural variation in within-
135 host evolution. To increase the evolutionary convergence signal by aggregating
136 mutations in functionally consistent categories, we annotated all genetic variants
137 using multiple datasets, including coding sequences, regulatory intergenic regions,
138 operons and gene ontologies (Figure 1C).

139

140 **Distinctive evolutionary patterns define nose-adapted, early infection-adapted
141 and late infection-adapted strains**

142 Based on the working hypothesis that *S. aureus* host adaptation patterns differ
143 according to whether the strains are nose-colonising, collected at an early stage of
144 infection or at a late infection stage (i.e associated with persistence or treatment
145 failure), we assessed whether it was possible to define i) general paradigms of
146 genetic variation and ii) specific convergence signatures. Thus, we classified within-
147 host acquired variants into three groups according to their most likely location in the
148 within-host phylogeny: (i) between colonising strains (type C>C); (ii) between
149 colonising and early infection adapted strains (type C>I); and (iii) between invasive

150 strains (type I>I). Overall, the 396 infection episodes included in the analysis allowed
151 us to independently assess 166 type C>C, 118 type C>I and 312 type I>I within-host
152 variants. In 95 cases there were sufficient samples to assess all 3 types within the
153 same episode (Figure 2A).

154 We have previously shown that invasive strains from persistent or relapsing
155 infections exhibit a high proportion of protein-truncating mutations (17). A similar
156 enrichment of protein-truncating variants was identified within invasive strains as
157 compared to strains from asymptotically colonised individuals (12, 27). We
158 reasoned that if this indicates genome degradation during infection, infecting strains
159 might also be enriched for other loss-of-function mutations caused by structural
160 variants, such as movement of insertion sequences (48) and large deletions, leading
161 to complete or partial gene loss (49). In addition, we hypothesised that mutations
162 and IS insertions in intergenic regions might contribute to altering gene expression or
163 activity by interfering with the expression of key genes or operons (50).

164

165 Therefore, we calculated the prevalence of intergenic mutations, protein-truncating
166 mutations, IS insertions and large deletions among all variants and compared it
167 between type C>C (colonising-colonising), type C>I (colonising-invasive) and type
168 I>I (invasive-invasive) variants. Strikingly, the distribution of mutations according to
169 the predicted effect differed substantially in invasive-invasive pairs when compared
170 to mutations identified between nose-colonising and invasive strains and within
171 colonising strains (Figure 2 and Table 2). As compared to type C>C variants,
172 variants emerging within the infecting strains were enriched for intergenic mutations
173 (neutrality index [NI] 2.5; $p = 1.8 \times 10^{-16}$) and protein-truncating mutations (NI 2.4; $p =$

174 4.8×10^{-10}). In contrast, no significant enrichment was observed among type C>I
175 variants.

176

177 While large deletions were significantly more enriched in type I>I variants (NI 4.0, $p =$
178 1.1×10^{-15}), the strongest evidence for enrichment (NI 19.9, $p = 1.6 \times 10^{-42}$) was
179 found for IS insertions. We and others have previously shown that new insertions of
180 IS256 may provide an efficient mechanism of genomic plasticity in invasive *S.*
181 *aureus* strains (17, 39, 50). Here, we expand this observation in a larger dataset and
182 show that this mechanism is not limited to IS256 (Figure 2 – figure supplement 2). As
183 shown in Figure 2, two invasive strains exhibited a burst of > 10 new IS insertions
184 (IS3 and IS256, respectively). It has been shown that IS activation occurs under
185 stress conditions, such as antibiotic exposure and oxidative stress (51), which is
186 consistent with the selection environment encountered by invasive strains. However,
187 these bursts occurred only in 2/1,068 adapted invasive strains.

188

189 Overall, these data support a model, where late infection-adapted strains show an
190 enrichment for variants that are predicted to exert a stronger functional impact, either
191 by producing a truncated protein or by potentially interfering with intergenic
192 regulatory regions, through point mutations or IS insertions. This strong genome
193 degradation signature appears to be specific to type I>I variants and was absent in
194 type C>I variants, suggesting that the bottleneck effect upon blood or tissue invasion
195 doesn't explain it. To assess whether this general enrichment of non-silent evolution
196 represented a signature of positive selection or derived from within-host gene
197 obsolescence occurring during invasive infection, we further investigated signals of

198 gene, operon and pathway specific enrichment across independent episodes of
199 infection.

200

201 **Gene enrichment analysis identifies significant hotspots of adaptation.**

202 To identify signatures of adaptation, we first counted how many times each coding
203 sequence was mutated independently across distinct colonisation/infection episodes
204 (Figure 3, Tables 3 and Table 3 – table supplement 1, Supplementary file 3). We
205 considered all protein-modifying mutations either predicted to cause a gain or loss of
206 function to the locus: non-synonymous substitutions, truncations, IS insertions or
207 deletions. To ensure consistency across the dataset, we restricted our analysis to
208 genes with a homologue in reference strain FPR3757 (excluding plasmid genes and
209 phage genes). Mutations were considered independent if they arose in distinct
210 colonisation/infection episodes. To assess whether the convergent signals were a
211 reliable indication of adaptation, we applied a gene enrichment analysis for protein-
212 altering mutations which computes a length-corrected gene-level enrichment of
213 protein-modifying mutations and estimates the significance of the enrichment for
214 each gene using Poisson regression (12).

215

216 When applying a Bonferroni-corrected significance threshold (4.6×10^{-5}), mutations in
217 *agrA* were highly significantly enriched across the entire dataset (45 fold enrichment,
218 $p=7.0 \times 10^{-28}$). Other significantly enriched genes were *agrC* (13 fold enrichment,
219 $p=2.8 \times 10^{-10}$), *stp1* (14 fold enrichment, $p=1.1 \times 10^{-7}$) and *mprF* (6 fold enrichment,
220 $p=4.6 \times 10^{-6}$). The gene *sucA* reached near-significance (5 fold enrichment, $p=6.8 \times 10^{-5}$).
221 Mutations in genes most significantly targeted by convergent evolution were
222 evenly distributed across the *S. aureus* phylogeny, indicating that these adaptative

223 mechanisms were not specific to selected lineages (Figure 3 – figure supplement 1).

224 Using dN/dS analysis, we confirmed signatures of positive selection in the most

225 significantly enriched genes, although only *agrA* reached statistical significance

226 (Figure 3 – figure supplement 2 and supplementary file 4).

227

228 We found that several genes with the most significant enrichment (*agrA*, *agrC*, *stp1*,

229 *sucA*) were recurrently mutated across all three within-host evolutionary scenarios,

230 implying a global role in *S. aureus* adaptation during colonisation and invasion. This

231 suggests partial adaptation of *S. aureus* strains upon invasion. It has been previously

232 shown that adaptive mutations, particularly within the quorum sensing accessory

233 gene regulator (*agr*), are enriched in invasive *S. aureus* strains, suggesting that

234 adapted strains are more prone to be involved in invasive disease (12, 27, 47, 52).

235 While the key role of *agr* was consistent with previous evidence from clinical and

236 experimental studies, the high number of recurrent *sucA* mutations was surprising.

237 This metabolic gene encodes for the α -ketoglutarate dehydrogenase of the

238 tricarboxylic acid cycle, and recent work has revealed the functional basis of its

239 potential role in adaptation. Its inactivation was found to lead to a persister

240 phenotype (53) and *sucA* was a hotspot of metabolic adaptation to antibiotics in a

241 recent *in vitro* evolution study (54).

242

243 To confirm that our gene enrichment analysis (focused on point mutations and IS

244 insertions and limited to genes with FPR3757 homologs) captured the large part of

245 adaptation, we analysed variation due to large deletions and copy number variation,

246 which were not included in the gene enrichment analysis. We observed multiple

247 independent deletions and amplifications mainly in phage genes (Figure 3 – figure

248 supplement 3 and Figure 3 – figure supplement 4). We also repeated the gene
249 enrichment analysis with all mutated genes (with and without FPR3757 homologs)
250 and found very similar results, with only two hypothetical proteins with no FPR3757
251 homolog among the genes with most significant enrichment (Figure 3 – figure
252 supplement 5).

253

254 **Combining multiple mechanisms of adaptation and multilayered annotation**
255 **increases the signal of convergent evolution**

256 To increase our ability to capture signatures of adaptation from convergent evolution,
257 we extended our analysis beyond coding sequences, to integrate the genetic
258 variation signals issued from intergenic mutations and IS insertions in intergenic
259 regions. This multi-layered annotation of mutated regions was shown to increase the
260 amount of information gained from *in vitro* adaptive evolution experiments (55). Such
261 methodology allows for an advanced classification of intergenic mutations based on
262 regulatory sequences including promoters and transcription units based on data
263 acquired from RNAseq experiments (56, 57).

264

265 Using this approach, we were able to assign 150/1237 (11%) of all intergenic
266 mutations and IS insertions to a predicted regulatory region. We found that the *agr*,
267 *sucAB*, *walKR* operons had the strongest convergent evolution signal with 28, 13
268 and 13 independent mutations (Supplementary file 5). Mutations within these loci
269 were significantly (*agr*, 12-fold enrichment, $p=1.1e-21$; *sucAB*, 4-fold enrichment,
270 $p=4.5e-5$) or near-significantly enriched (*walKR*, 3-fold enrichment, $p=1.7e-4$) (Figure
271 4). Interestingly, promoter mutations represented 2/13 (15%) of the *walKR* operon
272 mutations, indicating that potentially impactful intergenic variants may be missed

273 when considering only coding regions. Further, new IS insertions were found within
274 type I>I (invasive-invasive) variants: three insertions into *agrC* (predicted to
275 inactivate the gene, as shown previously in staphylococci (58, 59)) and an insertion
276 159 bp upstream of *walR*, in a region encompassing its cognate promoter. Together
277 with the strong enrichment for IS insertions within type I>I variants, the location of
278 these insertions in recurrently mutated operons suggests that IS insertions contribute
279 to the adaptive evolution of *S. aureus* during invasive infection.

280

281 **Adaptation within the invasive population is distinctive and strongly driven by**
282 **antibiotics.**

283 The excess of non-silent evolution (and potentially function-altering) within invasive
284 strains suggested that strong, specific selection pressure occurs within the invasive
285 populations (type I>I variants). We therefore assessed genes that appeared to be
286 specifically mutated or inactivated during infection. We performed our gene- and
287 operon-enrichment analysis for each type of within-host variants separately (i.e
288 within the colonising population, between colonising and invasive strains and within
289 the invasive population) (Figure 5).). We found that *agrA* mutations were highly
290 enriched in any group of variants, and particularly prevalent between colonising and
291 invasive strains (type C>I variants), consistent with a previous study that is included
292 in this analysis (12). Among type I>I variants (between invasive strains), a significant
293 enrichment was observed in *mpvF* (18 fold enrichment, $p = 2.8 \times 10^{-9}$), *agrC* (24 fold
294 enrichment, $p = 2.1 \times 10^{-7}$), *rpoB* (10 fold enrichment, $p = 8.8 \times 10^{-6}$). Other genes that
295 were strongly enriched in type I>I variants (below the Bonferroni-corrected threshold,
296 but above the suggestive significance threshold, Figure 5), included *walR* (22 fold
297 enrichment, $p = 3.5 \times 10^{-4}$), *stp1* (20 fold enrichment, $p = 4.2 \times 10^{-4}$), *yjbH* (19 fold

298 enrichment, $p = 5.4 \times 10^{-4}$), *sgtB* (19 fold enrichment, $p=5.5 \times 10^{-4}$) and *purR* (18 fold
299 enrichment, $p = 5.8 \times 10^{-4}$).

300

301 The enrichment for mutations in *mprF*, *rpoB*, *stp1*, *sgtB* and in the *walKR/yycH*
302 operon (11 fold enrichment, $p = 9 \times 10^{-9}$, see Figure 5 – figure supplement 1 for the
303 operon enrichment analysis) highlights the role of antibiotic pressure in shaping
304 adaptation within the invasive population, since these loci are hotspots of adaptation
305 to key anti-staphylococcal antibiotics that are often used in invasive infections
306 (rifampicin, daptomycin, vancomycin). For example, the essential two-component
307 regulator *walKR/yycFG* (and its associated genes *walH/yycH*) have been shown to
308 have a key role in vancomycin resistance in one of the within-host evolution studies
309 included in this analysis (41), while mutations in both *stp1* and *sgtB* have been
310 observed in vancomycin-adapted strains (60).

311

312 Notably, the most significant gene signatures in invasive strains might have been
313 selected in response to other selective pressures, including the host immune
314 response during infection. For example, *rpoB* mutations have been associated with
315 pleiotropic effects, including co-resistance to vancomycin, daptomycin and oxacillin
316 and immune evasion, suggesting a potential role in adaptation beyond the response
317 to the selective pressure from rifampicin (61). This hypothesis is supported by the
318 presence of mutations (such as the *rpoB* R503H substitution and N405 inframe
319 deletion) outside the rifampicin-resistance determining region

320

321 Pleiotropic phenotypes are also likely to underlie the enrichment of *yjbH* with
322 invasive strains, which was mutated four times (of which three were truncations), yet

323 only one mutations was found in colonising strains or early infection-adapted strains.
324 This gene has a cysteine-rich domain that is homologous to *dsbA* in *E. coli*. One of
325 its roles in *S. aureus* is to facilitate the ClpXP-dependent degradation of the
326 transcriptional regulator Spx (62). Inactivation of *yjbH* has been associated with
327 oxacillin (63) and vancomycin (64) resistance, impaired growth (65) and reduced
328 virulence in animal models (66), indicating that *yjbH* mutations may influence both
329 host-pathogen interaction and antibiotic resistance. Finally *purR*, a purine
330 biosynthesis repressor, has been recently characterised beyond its metabolic
331 function: interestingly it was shown to be a virulence regulator (67), where *purR*
332 mutants displayed higher bacterial counts following mice infection, increased biofilm
333 formation (68) and higher capacity to invade epithelial cells (69).

334

335 We perfomed a gene set enrichment analysis (GSEA), using gene ontology and
336 antibiotic resistance gene annotations (70). The GSEA, stratified by variant type,
337 showed significant enrichment only in type I>I (invasive-invasive) variants, further
338 underscoring the higher level of adaptation in this group (Figure 5 – figure
339 supplement 2 and supplementary file 6) and confirmed the broad functional
340 implications of the most enriched genes and operons with the invasive populations,
341 since among the ontologies that were significantly enriched within the invasive
342 population, we found the categories “DNA binding” (normalised enrichment score
343 [NES] = 1.6, false-discovery rate (FDR)-ajusted p = 9x10⁻⁴), “pathogenesis” (NES =
344 1.7, ajusted p = 4x10⁻³) and “antibiotic response” (NES = 1.8, adjusted p = 7 x 10⁻³).

345

346 Taken together, these findings point to six key genetic loci that appear to have an
347 important role in *S. aureus* adaptation during invasive infections. These loci

348 are associated with either antibiotic resistance (*mpfF*, *rpoB*, *stp1*, *sgtB*, *walKR*),
349 pathogenesis (*agrAC*, *purR*) or both (*yjbH*).

350

351 **A mutations co-occurrence network defines loci under within-host co-**
352 **evolutionary pressure**

353 Epistasis, defined as the interaction of multiple mutations on a given phenotype (71),
354 plays a role in adaptive evolution in bacteria, particularly in antibiotic resistance (72-
355 74). Whether epistatic interactions could promote *S. aureus* adaptation during
356 infection remains unknown. Identifying these interactions would enable
357 identification of combinations of mutations underlying bacterial adaption during
358 infection and refine the prediction of infection outcomes. Here, we assessed co-
359 occurrence of mutations and mutated genes across independent episodes of
360 colonisation/infection. While co-occurrence may simply result from co-selection (e.g.
361 simultaneous exposure to two different antibiotics), it may also indicate putative
362 epistatic interactions, that could be explored in terms of potential impact on adaptive
363 phenotypes (75).

364

365 First, we explored co-occurrence of mutations, and found only one case where the
366 same mutations co-occurred in more than one independent episode. The two
367 mutations were an inframe deletion within hypothetical protein SAUSA300_2068 and
368 a A60D substitution of the gene *ywlC*. These genes are closely located in FPR3757.
369 While the co-occurrence could be explained by recombination, recombination is
370 expected to be rare amongst within-host *S. aureus* populations in general (43) and
371 even rarer within invasive strains. *YwlC* is a threonylcarbamoyl-AMP synthase *in E.*
372 *coli*, thus it is possible that SAUSA300_2068 is also a ribosomal protein. Ribosomal

373 proteins can display regulatory activity (76), and could plausibly be targets of
374 adaptation to both antibiotics and the host/intracellular survival. This specific case of
375 convergent co-occurrence of mutations was detected within type I>I variants.

376

377 When assessing interactions at gene level (i.e. co-occurrence of the same altered
378 protein sequences across independent episodes), we found the strongest interaction
379 between the *agrA* and *agrC* genes (Figure 6). While this is consistent with the high
380 convergence of mutations in the *agr* locus, this suggests that strains acquire multiple
381 mutations within the locus, possibly further impacting *agr* activity. Interestingly, no
382 convergent co-occurrence signature compatible with possible epistasis was
383 observed within the *walKR* locus, the other operon with a high number of
384 independent mutations; which could be due to the essentiality of *walKR* in *S. aureus*
385 (77). Collectively, *agr* locus mutations interacted with 17 other mutated genes, the
386 strongest interaction being with *stp1*. Since *stp1* (a serine/threonine phosphatase)
387 has been previously associated with virulence regulation (78), this interaction
388 potentially indicates another mechanism by which adapted strains fine-tune the gene
389 expression profile that is already altered by *agr* mutations.

390

391 Another moderately strong interaction was observed between *rpoB* and *parC*, which
392 were co-mutated in three independent episodes. Given the association of *parC*
393 mutations with fluoroquinolone resistance (79), this interaction is likely to be an
394 example of co-selection due to co-exposure to fluoroquinolones and rifampicin.

395

396 **Clinical correlates of adaptive signatures within colonising and invasive**
397 **populations**

398 Genetic signatures of bacterial adaptation have been associated with infection
399 extent, for example enabling the prediction of extraintestinal infection with
400 *Salmonella enterica* (80). We have previously shown that adaptive mutations are
401 enriched in invasive infections, however, it is unclear whether bacterial adaptation is
402 more likely to be associated with distinctive clinical syndromes. To identify clinical
403 correlates of adaptive signatures we classified colonisation and infection episodes
404 based on the sites of collection and on clinical data obtained from the publications
405 (table 1 and Figure 7 – figure supplement 1). We then used the Jaccard index and
406 network analysis to compute node centrality as a global measure of adaptation for
407 each independent episode. The Jaccard index can be used as a simple marker of
408 the proportion of shared mutated genes between pairs of colonisation or infection
409 episodes (81). Node centrality allows to simultaneously take into account the
410 strength of similarity between independent episodes (Jaccard index) and the number
411 of pairs with shared mutated genes (number of connections). Here, we limited the
412 analysis to the 20 most significantly enriched genes with each type of variant.

413

414 Our network analysis showed that adaptation was present in only a minority of
415 episodes within each type of variant (Figure 7 – figure supplement 2). With a
416 definition of adaptation based on a centrality value of more than 0, we found that the
417 proportion of adaptive episodes was 43%, 20% , 22% with type C>C, C>I and I>I
418 variants, respectively. In addition certain clinical syndromes were more strongly
419 associated with adaptation. Within the colonising population (type C>C variants),
420 almost 80% of cystic fibrosis episodes were adaptive, as opposed to one third of

421 episodes of skin colonisation in atopic dermatitis (Figure 7AB). This is consistent with
422 within-host evolution studies showing strong convergent evolution signals among
423 bacterial populations colonising individuals with cystic fibrosis, not only in case of *S.*
424 *aureus* colonisation (25), but also *Pseudomonas aeruginosa* (7) and *Mycobacterium*
425 *abscessus* (82), however, one study found adaptive evolution signals in atopic
426 dermatitis (83). We also observed that adaptation among infection episodes
427 correlated with infection extent. Episodes of infective endocarditis episodes
428 displayed higher adaptation metrics (46% with centrality > 0) than bacteraemia with
429 additional infection foci (28%) and bacteraemia without focus (17%) (Figure 7 D-E).

430

431 To explore the syndrome-specificity of adaptation signatures, we mapped mutations
432 in the most significantly enriched adaptive genes to clinical syndromes of
433 colonisation and infection (Figure 7 panels C and F). As expected, syndromes with
434 high prevalence of adaptation had higher numbers of episodes with adaptive
435 mutations; however, some genes appeared to be preferentially mutated. For
436 example, *rpsJ*, *stp1* and SAUSA300_1230 were over-represented in cystic fibrosis,
437 while no clear pattern of mutations was discernible for nasal carriage episodes.
438 Within infection syndromes, *mprF* and *purR* mutations were more prevalent in
439 endocarditis, and *yjbH* mutations were only found in severe infections (bacteraemias
440 with additional foci and endocarditis). Some genes appeared to be distinctive for low
441 adaptation groups (atopic dermatitis, skin infections), however the low number of
442 adaptative mutations prevented an accurate assessment of these profiles.

443

444 **DISCUSSION**

445 Within-host evolution of bacterial pathogens such as *S. aureus* is thought to be
446 governed by a combination of positive selection for variants that confers an
447 advantage within the host, and fixation of mutations owing to genetic drift and
448 relaxation of purifying selection (19, 84). Sudden changes in the effective population
449 size (bottlenecks) can cause genetic drift, for example when a single or few
450 bacterial cells invade the bloodstream or when a secondary infection foci is
451 established in tissues and organs. Consistent with this view, animal studies have
452 shown that after infecting the blood with a polyclonal population, bacteraemic
453 infection is established stochastically by a single clone (85, 86). On the other hand,
454 several lines of evidence support the role of positive selection and adaptive evolution
455 during *S. aureus* infection. First, adaptive phenotypic features appear to be acquired
456 during infection. The most obvious adaptative phenotype is secondary resistance to
457 anti-staphylococcal antibiotics such as rifampicin, vancomycin (16), daptomycin (87),
458 oxacillin (15). Crucially, these resistance phenotypes can be associated with
459 pleiotropic, patho-adaptative phenotypes such as small colony variant and immune
460 evasion (61, 88, 89). Further, phenotypic adaptation (e.g. loss of toxicity) has been
461 observed upon transition from colonisation to infection (90), supporting the concept
462 that invasive infection is linked to patho-adapted strains. At the molecular level, an
463 excess of protein-truncating mutations in invasive strains (17) and in late colonising
464 strains leading to infection (27) have been noted. While this observation alone could
465 be explained by relaxed constraint resulting from reduced population size (84), it has
466 been suggested that loss of gene function might be a common adaptation
467 mechanism of within-host evolution (21), as supported by evidence of gene- or

468 pathway-specific enrichment of mutations across independent infection episodes
469 (12).

470

471 Despite support for adaptive evolution from previous studies, it has been difficult to
472 identify specific molecular signatures of adaptation during infection, due to the limited
473 power of previous within-host studies of bacteraemia and other serious *S. aureus*
474 infections, that were often limited to a restricted number of episodes. To increase our
475 ability to identify signatures of adaptation and find significantly enriched loci, we
476 analysed multiple sources of genetic variation (point mutations, large deletions, IS
477 insertions, copy number variants) in a large collection of independent episodes of *S.*
478 *aureus* colonisation and infection from 25 studies. We predicted that the main
479 advantage of our approach would be to increase the ability of detecting convergence
480 of genetic variants arising during invasive infections as opposed to those detected
481 during the colonisation and upon transition from colonisation to infection. To test this
482 hypothesis, we classified within-host variants based on their likely position in the
483 within-host phylogeny (Figure 1D).

484

485 Bacterial adaptation is promoted by genomic plasticity, however, within-host
486 evolution is characterised by low genetic variation (17). Based on our previous
487 genomic studies of *S. aureus* bacteraemia, we reasoned that chromosome structural
488 variants may provide an additional mechanism to increase genetic variation during
489 infection. Here, we found that new insertions of insertion sequences (IS) are strongly
490 enriched during invasive infection. However, despite this 20-fold enrichment, IS
491 insertions remained a rare source of variation even within invasive strains and
492 appeared to have a selective contribution to adaptation (i.e. limited to specific loci

493 such as *agrC*). Similarly, large deletions and copy number variants appeared to play
494 a less prominent role in adaptation, although we didn't include them in our
495 enrichment analysis,

496

497 Together with the enrichment for loss-of function mutations, which is another feature
498 of evolution within the invasive population in our analysis, these IS movements
499 suggest that a pattern of reductive evolution emerges during within-host evolution of
500 invasive *S. aureus*. This excess of genome degradation might be related to less
501 effective purifying selection in the invasive population due to a decrease in effective
502 population size and a shorter evolutionary timescale (84). However, our data indicate
503 that these changes converge to specific genes, operons and pathways, suggesting
504 an adaptative benefit. Reductive evolution has been described in several
505 "commensal-to-pathogen" settings (49). Although niche adaptation through reductive
506 evolution has been described in extracellular pathogens (91), a smaller (reduced)
507 genome is an hallmark of obligate intracellular endosymbiotic bacteria (92). Since it
508 appears that invasive *S. aureus* is able to reside intracellularly (promoting
509 dissemination through mobile phagocytes during *S. aureus* sepsis (93, 94), and
510 immune evasion), it is plausible that this pattern of reductive evolution reflects an
511 adaptation of invasive *S. aureus* to an invasive and intracellular lifestyle, as it has
512 been shown for other facultative intracellular pathogens such as non typhoidal
513 *Salmonella* (19). However, it is possible that these signatures of reductive evolution
514 might be only temporary, as genome degradation might be present only in a minority
515 of strains or be reversible; moreover, loss-of-function mutations are expected to be
516 more likely than gain-of-function mutations.

517

518 Beside reductive evolution, another distinctive feature of within-host evolution during
519 invasive infection were intergenic mutations (both point mutations and IS insertions).
520 In a within-host evolution study of *S. pneumoniae* colonisation, it was shown that
521 intergenic sites were under convergent evolution (10). Mutations in promoter
522 sequences of some core genes can play an important role in antibiotic resistance as
523 it was repeatedly shown for *pbp4* and resistance to beta-lactam antibiotics (95). The
524 role of intergenic mutations in within-host evolution was shown in a study of *P.*
525 *aeruginosa* infection, where convergent evolution targeted several intergenic
526 regulatory regions including upstream of antibiotic resistance genes (24).

527

528 Previous work on within-host evolution by our group (included in this analysis) has
529 established that *agrA* mutations are significantly enriched upon transition from
530 colonisation to infection (12). In addition, we have shown through genomics and
531 targeted mutagenesis that mutations in key genes such as *walKR* (41) and *rpoB* (96)
532 play a key pathoadaptive role in selected cases of persistent *S. aureus* infections. In
533 this study, we increased our ability to discover potential targets of adaptation by
534 analysing several mechanisms of genetic variation and applying several layers of
535 annotation. As compared to previous work on *S. aureus*, this approach provides a
536 higher-resolution picture of within-host evolution and adaptation. Importantly, this
537 analysis remains robust after removing more than 1,000 sequences from the largest
538 within-host study included (Figure 3 – figure supplement 6). We increase here the
539 generalisability of our findings. We expand the list of genes targeted by convergent
540 evolution and show that there are distinctive adaptation pathways in colonising and
541 invasive populations. We confirm that the dominantly mutated loci belonged to the
542 *agr* locus, in particular *agrA* and *agrC*. This finding is consistent with a large body of

543 literature that predated the genomic era (97), that supports the role of the *agr* locus
544 as the master regulator of gene expression in *S. aureus*. *Agr*-mediated adaptation
545 was so important that we found a highly significant enrichment of *agr* mutations across
546 all type variants, including within colonising strains (type C>C variants). Shopsin *et*
547 *a./l* showed that ~10% of healthy *S. aureus* carriers held an *agr*-defective strain and
548 that prior hospitalisation was significantly associated with *agr*-defective status,
549 suggesting prior adaptive pressures (98).

550

551 Consistent with the distinctive general patterns of evolution displayed during invasive
552 infection, some genes and loci were specifically mutated within invasive strains.
553 Some of these genes were emerging targets of *S. aureus* pathogenesis *in vivo*, such
554 as *purR* and *yjbH*, that were not singled out in previous within-host evolution
555 investigations. Others were known determinants of antibiotic resistance, including
556 *mprF*, *rpoB* and the *walKR* operon. This underscores the crucial role of antibiotic
557 exposure in shaping adaptive evolution during invasive infection. A recent study of
558 within-host evolution during cystic fibrosis found that resistance genes were hotspots
559 of convergent evolution in this population, which is frequently treated with antibiotics
560 and shows features of phenotypic adaptation (25).

561

562 While most mutations in adaptive loci were substitutions within the coding sequence,
563 about 40% of *walKR* operon mutations were located outside of the coding regions of
564 *walR* and *walK*, emphasising the need to study intergenic mutations and mutations
565 throughout an operon to capture adaptive signatures. This observation highlights the
566 importance of expanding the analysis of intergenic mutations for the detection of
567 adaptive mutations, in particular those linked to antibiotic resistance.

568

569 If within-host evolution represents adaptative evolution it is possible that adaptation
570 involved an accumulation of mutations and possibly epistatic mechanisms. Our data
571 show that some mutations are specific for invasive strains; these mutations may
572 reflect late adaptation, occurring after evolution during colonisation in the nose and
573 upon transition from colonisation to infection, and thus occurring after adaptive
574 mutations were acquired during earlier stages. This evolutionary pattern of stepwise
575 adaptation (or adaptive continuum) encompassing the entire within-host evolutionary
576 arch has been well described for cancer (99) and has been also investigated in a
577 study of transition from colonisation to infection (27). One way to capture this is
578 mutation co-occurrence analysis. Here, we show mutation co-occurrence within the
579 *agr* operon, but also co-occurrence of the same mutations in two uncharacterised
580 proteins in *S. aureus*. Our network of mutation co-occurrence linked to *agrAC*
581 mutations might suggest a potential pathway of stepwise adaptation following initial
582 mutations acquisition in the *agr* locus, an hypothesis that has been explored in one
583 of studies included in our analysis (47).

584

585 While combining multiple studies allowed us to increase statistical power in order to
586 detect genome-wide convergent signals of adaptation, this approach has some
587 limitations. The quality of the publicly available sequences and metadata can be
588 heterogenous, despite performing quality control assessment, for example due to
589 different read coverage across studies. In addition, detection of structural variants
590 from short reads is not as accurate as from long reads; for example, chromosomal
591 inversions can be missed if they inversion site span is larger than the insert site of
592 the paired-end reads (89).

593

594 Ultimately the goal of detecting adaptive signals is to identify new mechanisms of
595 pathogenesis or resistance to therapeutic targets and to inform prediction of clinical
596 outcomes. So far, studies have failed to show consistent associations between
597 specific clinical outcomes and genetic features of infecting (or colonising) *S. aureus*
598 strains. This might be related to the dominance of host / environmental factors, but it
599 could also be linked to the limited power of studies performed so far. By contrast,
600 within-host evolution studies are an elegant approach to identify signatures of
601 adaptation that might be candidate markers of important clinical outcomes, such as
602 infection risk in case of colonisation or treatment failure in case of infection. Here, we
603 show that adaptation signatures are at least partially specific to colonisation,
604 infection and upon transition from colonisation to infection, and that adaptive
605 changes are more frequent in distinctive infection episodes (complicated
606 bacteraemia, endocarditis). These findings suggest that adaptive signatures might
607 be indicative of important clinical outcomes. In the future, precision medicine in
608 infectious diseases could follow the lead of cancer genomics, where within-host
609 evolution studies have tracked the evolution of cancer clones and enabled the
610 detection of high risk mutations early.

611

612 MATERIAL AND METHODS

613 Literature search

614 We conducted a search of articles indexed in PubMed before the 11th August 2020
615 using the keyword “aureus” in combination with either “genomics” or “whole genome
616 sequencing” and with either “within-host evolution” or “in vivo evolution” or
617 “adaptation” or “bacteraemia”. The records retrieved through this search were

618 combined with additional citations identified through other sources. After removing
619 duplicates, this resulted in 815 citations that were screened based on following
620 inclusion criteria: i) Whole-genome sequencing of human *S. aureus* isolates; ii) > 1
621 *S. aureus* isolates sequenced per individual; iii) Sequences (reads or assemblies)
622 publicly available; iv) Minimum sequences metadata available (either with the
623 manuscript or linked to the sequences): patient ID, date of collection (or collection
624 interval in reference to a baseline isolate), source of the sample. After excluding
625 studies not satisfying the inclusion criteria (730 based on the title, 46 based on the
626 abstract and 15 after reviewing the full text), we kept 24 within-host evolution studies.

627

628 **Extraction of sequences metadata**

629 For each of the included studies, following variables were extracted either from reads
630 metadata (when available) or from the publication/supplementary data: identifier
631 linking the sequences to a patient or an episode of infection, date of collection (when
632 available) or collection interval in reference to a baseline isolate), site of collection of
633 the isolate. Isolates were broadly categorised in “colonising” and “invasive” based on
634 the site of collection, when the information was unambiguous (e.g. “nose” for
635 “colonising” or “blood” for “invasive”). When the information on the body site was not
636 sufficient (e.g. “skin” or “lung”), the categorisation was based on further details
637 provided in the publication. When available, phenotypic metadata and antibiotic
638 treatments were also extracted from the publication. We used clinical and site data to
639 classify colonisation episodes in “nasal carriage”, “atopic dermatitis” and “cystic
640 fibrosis” and infection episodes in “skin infection” (skin infection site surgical site
641 infection without other foci), “osteoarticular infection” (bone/join infection without
642 other foci), “bacteraemia without focus” (bloodstream infection, no other foci, expect

643 for vascular catheter or skin), “bacteraemia with focus (bloodstream infection with
644 other focus involving the lung, nervous system, bone and joints or internal organs),
645 and “endocarditis” (based on diagnosis reported in the publication or in the clinical
646 metadata).

647

648 **Sequences processing**

649 Sequences (reads and assemblies) and metadata were downloaded from the
650 European Nucleotide Archive (ENA) and the National Center for Biotechnology
651 Information (NCBI), respectively using the BioProject accession or the genome
652 accession. Quality assessment of the reads was performed by calculating mean read
653 depth and the fraction of *S. aureus* reads using Kraken 2, v2.0.9-beta (100) and by
654 extracting metrics from reads assemblies constructed using Shovill, v1.1.0
655 (<https://github.com/tseemann/shovill>) and annotated using Prokka, v1.14.6 (101).
656 Sequence type (ST) was inferred from the assembly using Mlst, v2.19.0
657 (<https://github.com/tseemann/mlst>) and resistance genes were detected using
658 Abricate, v1.0.1 (<https://github.com/tseemann/abricate>). Reads were discarded if the
659 mean coverage depth was below 35, the majority of reads were not *S. aureus* or the
660 size of the assembly was below 2.6 megabases. Assemblies downloaded from the
661 NCBI repository were discarded if the genome size was below 2.6 megabases.

662

663 **Sequences from the CAMERA2 trial**

664 We collected *S. aureus* strains from bacteraemia episodes included in the
665 CAMERA2 trial (Combination Antibiotics for Methicillin Resistant *Staphylococcus*
666 *aureus*), where at least 2 strains per episode were available. The CAMERA2 trial
667 was performed between 2015 and 2018 in Australia, New Zealand, Singapore and

668 Israel, and randomised participants with methicillin-resistant *S. aureus* (MRSA)
669 bacteraemia to either monotherapy with vancomycin or daptomycin or combination
670 therapy with vancomycin or daptomycin plus an antistaphylococcal beta-lactam
671 (flucloxacillin, cloxacillin or cefazolin) (26). Strains were isolated from -80C glycerol
672 onto horse-blood agar. Species was confirmed using Matrix-assisted laser
673 desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS). Bacterial
674 whole-genome sequencing was performed from single colonies on the Illumina
675 NextSeq platform. Reads were checked for quality, assembled and annotated as
676 described above.

677

678 **Global phylogeny**

679 To generate a global alignment of all sequences, reads and shredded assemblies
680 were mapped to reference genome USA300 FPR3757 (assembly accession:
681 GCF_000013465.1) (using Snippy, v4.6.0 (<https://github.com/tseemann/snippy>)). The
682 core genome alignment was obtained using Snippy; sites with > 10% gaps were
683 removed using Goalign (102) and constant sites were removed using SNP-sites
684 (103), for a final length of 186,825 bp. A maximum-likelihood phylogenetic tree of
685 2,590 sequences (those kept in the analysis after excluding genetically unrelated
686 strains, see below) was inferred using IQ-TREE, v2.0.3 (104).

687

688 **Variant calling**

689 We have previously shown that the accuracy of variant calling in within-host
690 evolution analyses is improved when mapping reads to an internal draft assembly as
691 opposed to a closely related closed genome (17). Here, we applied the same
692 approach, where we selected the internal reference among the sequences from the

693 same patient or episode. When available, the oldest colonising strain was selected.
694 When only sequences from invasive strains were available, the oldest strain
695 (baseline strain) was selected. When multiple sequences were available per sample
696 (e.g multiple colonies sequenced per plate) or at the same date, the reference was
697 randomly selected among them. Snippy with default parameters (minimum reads
698 coverage 10, minimum read mapping quality 60, minimum base quality 13) was used
699 for variant calling. To further improve the accuracy of the calls, we masked variants
700 called from reference reads and those at positions where reference reads had a
701 coverage below 10 (using the BEDTools suite (105)).

702

703 **Filtering of genetically unrelated sequences**

704 The threshold for removing genetically unrelated sequences was set empirically at
705 100 episode-specific variants based on the upper Tukey's fence of the distribution of
706 the number of variants in same-episode isolates belonging to the same ST (Figure 2
707 – figure supplement 1).

708

709 **Detection of chromosome structural variants**

710 Using BWA-MEM, reads and shredded contigs were aligned to the closest available
711 complete genome (either internal to the dataset or selected from the NCBI repository
712 based on the mash distance). To detect large deletions (≥ 500 bp), reads coverage
713 was compared between the internal reference and the sequences within every
714 episode using BEDTools, as described in (17). To detect new insertion sequences
715 (IS) insertions, split reads were extracted, filtered and annotated as described in (17).
716 We used the R package CNOGpro (106) to detect 1000 bp windows with an
717 estimated copy number above one as compared to the internal reference. The

718 package calculates the reads coverage per sliding windows of the chromosome,
719 performs a GC bias normalisation and infers copy number state using a Hidden
720 Markow Model. We ran the package with default parameters, with the exception of
721 the length of the sliding window that was set at 1000 bp. As with deletions, we used
722 BEDTools to subtract regions of the internal reference that had already an increased
723 copy number.

724

725 **Internal variant annotation**

726 To ensure a consistent annotation of mutated genes across independent episodes,
727 we clustered amino-acid sequences using CD-HIT, v4.8.1 with an identity threshold
728 of 0.9. The BEDTools suite was used to annotate mutated intergenic regions with
729 upstream and downstream coding regions and the distance separating the mutation
730 from the start or the end of the gene. For the operon analysis, intergenic mutations
731 were classified according to their location within a presumed promoter based on
732 blasting the sequence of unique promoters (as determined in (57)) on the draft
733 assembly of the internal reference. Phage genes were annotated using blastp and
734 the PhageWeb database (<http://computationalbiology.ufpa.br/phageweb/>).

735

736 **Variant annotation using reference strain FPR3757**

737 To compare mutated genes across separated episodes we used blastp to identify
738 homologs of each CD-HIT cluster of mutated genes in USA300 FPR3757. Genes in
739 FPR3757 were further annotated using the database provided in the AureoWiki
740 repository (107), operon annotations of FPR3757 were retrieved from Microbes
741 Online (108). Only protein-altering variants in genes with FPR3757 homologues

742 (excluding plasmid genes and phage genes) were kept for the analysis of
743 convergence at gene and operon level and the gene enrichment analysis.

744

745 **Classification of variants.**

746 Mutational and structural variants were classified in to type C>C (within colonising
747 strains), type C>I (between colonising and invasive strains) and type I>I (within
748 invasive strains) as follows: all variants arising in colonising strains were classified as
749 type C>C, while variants among invasive strains were classified as type C>I if they
750 were found in a baseline invasive strain (defined as the oldest invasive strain; when
751 multiple sequences were available at same time, the baseline invasive strain was
752 selected randomly), and as type I>I if they were found between invasive strains but
753 not on the baseline invasive strain. This approach is based on the assumption that
754 co-infection or superinfection is rare, as we have shown previously for bacteraemia
755 (17).

756

757 **Calculation of the neutrality index.**

758 A modified McDonald-Kreitman table was compiled a described in (109), where a
759 ratio was calculated between non-synonymous, protein-truncating, IS insertions,
760 intergenic and deletion variants and synonymous variants. The neutrality index was
761 obtained by dividing the ratio calculated above for type C>I (colonising-invasive) and
762 type I>I (invasive-invasive) by the ratio for type C>C (colonising-colonising) variants,
763 that were used as reference group. Significance was tested by Fisher test.

764

765 **dN/dS analysis**

766 We used the R package dNdScv (110) to obtain dN/dS ratios for non-synonymous
767 mutations, indels and missense mutations (stop codons) for all FPR3757 genes,
768 based on variants called when mapping all reads on FPR3757 and after subtracting
769 variants from the internal reference reads and variants in positive where internal
770 reference reads had a low coverage. Since this analysis could be hampered by
771 potential false-positive variants resulting from mapping reads on a single reference
772 (17), we also used our curated list of within-host mutations obtaind from episode-
773 specific variant calling to calculate crude dN/dS ratios by dividing the number of
774 protein modifying mutations by the number non-synonymous mutations and
775 computed p values by Fisher exact test as in (25).

776

777 **Gene and operon enrichment analysis.**

778 We calculated the enrichment of protein-altering mutations across all coding regions
779 of FPR3757 (excluding plasmid genes and phage genes) using the approach
780 described in (12). The variant enrichment per gene i was calculated as follows:
781 $(N_i/L_i)/(\Sigma_n/\Sigma_l)$, where N_i is the number of variants per gene i , L_i is the length of gene i ,
782 Σ_n is the total number of variants and Σ_l the total length of the genes. We used
783 Poisson regression to model the number of variants per gene j under the null
784 hypothesis (no enrichment), as as defined by the equation $\lambda_0 L_j$, where λ_0 is the
785 expected number of variants in any gene and L_j is the the gene length. Under the
786 alternative hypothesis (enrichment of variant in gene i), the estimated number of
787 variants is $\lambda_i L_i$ for gene i , and $\lambda_1 L_j$ for any other gene j . The model parameters λ_0, λ_1 ,
788 λ_i were estimated using maximum likelihood and tested for significance using the
789 likelihood ratio test. The genome-wide significance cut-off was calculated using the
790 Bonferroni correction (0.05 divided by the number of unique genes or operons) and

791 the suggestive significance cut-off (1 divided by the number of unique genes or
792 operons), as implemented for bacterial genome-wide associated studies (GWAS) in
793 (22).

794

795 **Gene set enrichment analysis**

796 For used the PANNZER plateform (111), to retrieve a gene ontology annotation of
797 FPR3757 based on the GO terms. We modified the “antibiotic response” category by
798 adding a curated list of antibiotic resistance genes downloaded from the NCBI AMR
799 gene reference database (70). The gene set enrichment analysis (GSEA) was
800 performed as implemented in the R package clusterProfile (112). Genes with a
801 FPR3757 homolog were ranked according to the significance of the enrichment of
802 protein-modifying mutations (gene enrichment analysis, see above) and the GSEA
803 was carried out with a minimum gene set size of 10 and using the false discovery
804 rate (FDR) method for adjustement for multiple testing.

805

806 **Mutation co-occurrence analysis**

807 To detect co-occurrence of mutations and mutated genes across independent
808 episodes, we constructed a co-occurrence matrix using the R package cooccur
809 (113). A co-occurrence of mutations or mutated genes in at least two independent
810 episodes was interpreted as convergent and as a sign of potential epistatic
811 interaction. The network of co-occurrence of mutated genes was visualised using the
812 R package ggraph (<https://cran.r-project.org/web/packages/ggraph/index.html>)

813

814 **Network analysis of adaptation signatures**

815 The pairwise calculation of the Jaccard index between set of mutated genes was
816 performed in R. The calculations were performed both with the entire set of mutated
817 FPR3757 genes and with the 20 most significantly enriched genes in each group of
818 variants. A network of shared mutated genes between independent episodes was
819 constructed using ggraph, where edges represented episode connections based on
820 rthe Jaccard index. We used the R package tidygraph to extract the node centrality
821 (function centrality_degree()) as a summary measure of the degree of adaptation of
822 the episodes. The network graph and analysis was performed for each group of
823 variants separately.

824

825 **Data availability**

826 The CAMERA2 isolates reads included in this study are available in the European
827 Nucleotide Archive under Bioproject accession no. PRJEB50796.

828

829 **Code availability**

830 Scripts used to call mutations and structural variants, annotate all variants and
831 perform the gene enrichment analysis are deposited on github at
832 https://github.com/stefanogg/staph_adaptation_paper

833 **FIGURES**

834 **Figure 1.** Overview of the *S. aureus* within-host evolution analysis framework. (A)
835 Simulated phylogenetic tree illustrating within-host evolution of *S. aureus*
836 colonisation and infection. This model assumes two genetic bottlenecks (dotted
837 lines); upon transmission, and upon transition from colonisation to invasive infection.

838 (B) Sites and timing of within-host samples and number of genomes per sample
839 define five prototypes of within-host evolution studies, each with colonising-
840 colonising, colonising-invasive or invasive-invasive comparisons in different
841 combinations: from top to the bottom: multiple colonising samples and one invasive
842 samples; one colonising and one invasive sample; multiple colonising samples;
843 multiple invasive samples; multiple colonising and invasive samples. (C) Approach to
844 capture signals of adaptation across multiple independent episodes of
845 colonisation/infection through detection of multiple genetic mechanisms of adaptation
846 from short reads data and multi-layered functional annotation of the genetic variants
847 using multiple databases including characterisation of intergenic regions (promoters),
848 operon prediction, and gene ontology (GO). (D) Statistical framework for the gene,
849 operon and gene set enrichment analysis. Counts of independent mutations with
850 likely impact on the protein sequence (non-synonymous substitutions, frameshifts,
851 stop codon mutations, IS insertions) were computed for each genes with a FPR3757
852 homolog. Gene counts (with the addition of intergenic mutations in promoter regions)
853 were aggregated in operons and gene ontologies. Gene and operon counts were
854 used to fit Poisson regression models to infer mutation enrichment and significance
855 of the enrichment. Gene ontologies counts and gene enrichment significance were
856 used to run a gene-set-enrichment analysis (GSEA). To illustrate the approach, the
857 example of the gene *wa/R* is provided in italic.

858 **Figure 2.** (A) Maximum-likelihood phylogenetic tree of 2,590 *S. aureus* sequences
859 included in the study. The tree is annotated (starting from the inner circle) with the
860 most prevalent sequence types (ST), presence/absence of the *mecA* gene,
861 compartment of isolation (colonising or invasive) and year of publication. (B)
862 Summary of 396 independent episodes of *S. aureus* colonisation or infection

863 categorised according to whether they allowed comparing colonising-colonising
864 (C>C), colonising-invasive (C>I) or invasive-invasive (I>I) strains, or a combination of
865 them. (C) Evidence of a distinctive pattern of adaptation in late infection-adapted
866 strains (type I>I variants). For each type of comparison (type C>C, colonising-
867 colonising; type C>I, colonising-invasive; type I>I, invasive-invasive), the cumulative
868 curves display the accrued number of intergenic mutations, truncating mutations, IS
869 insertions and large deletions as a function of the total number of mutations. Genetic
870 events were counted once per episode, regardless of the number of strains with the
871 mutation. The sequence of mutations events in the cumulative curves is random.

872 **Figure 2 - figure supplement 1.** Number of episode-specific variants in same-
873 episode strains having the same sequence type (ST) as the internal reference vs.
874 isolates with a different ST. The dashed line represents the mutation threshold used
875 to remove genetically unrelated strains with the same episode.

876 **Figure 2 - figure supplement 2.** Distribution of new IS insertions by classification of
877 the transposase and by major sequence types (ST). (A) Distribution of the 9 major
878 ST among 2,590 strains. (B) Number of independent IS insertions by ST group and
879 type of transposase.

880 **Figure 3.** Top 20 genes with the most significant mutation enrichment across the
881 entire dataset. (A) Significance of the enrichment for protein-altering mutations. The
882 dashed line depicts the Bonferroni-corrected significance threshold, red circles and
883 blue circles represent genes with p values below and above the Bonferroni
884 threshold, respectively. (B) Enrichment of protein-altering mutations (C) Bar plots of
885 independent mutations separated in 3 panels according to the type of variant (type
886 C>C: colonising-colonising; type C>I: colonising-invasive; type I>I: invasive-invasive)

887 and coloured according to the class of mutation. (D) Gene maps with type and
888 positions of mutations.

889 **Figure 3 - figure supplement 1.** Mapping of mutations in the 10 most significantly
890 enriched mutated genes across the entire dataset. The maximum-likelihood
891 phylogenetic tree was inferred from the core genome alignment of 2,590 isolates.

892 **Figure 3 - figure supplement 2. dN/dS values for non-synonymous mutations
(A), indels (B) and nonsense mutations (stop codons) (B) for FPR3757 genes.**
893 Only the 20 most significant genes with positive selection (dN/dS for missense
894 mutations > 1) are shown.

895 **Figure 3 - figure supplement 3.** Most frequently deleted genes in large deletions.

896 **Figure 3 - figure supplement 4.** Most frequently enriched genes in copy number
897 variations.

898 **Figure 3 - figure supplement 5.** Gene convergence analysis of all mutated genes
899 (i.e. including both genes with FPR3757 homolog and no FPR3757 homolog). Top
900 20 genes with the most significant mutation enrichment across the entire dataset. (A)
901 Significance of the enrichment for protein-altering mutations. The dashed line depicts
902 the Bonferroni-corrected significance threshold, red circles and blue circles represent
903 genes with and without FPR3757 homolog, respectively. (B) Enrichment of protein-
904 altering mutations (C) Bar plots of independent mutations separated in 3 panels
905 according to the type of variant (type C>C: colonising-colonising; type C>I:
906 colonising-invasive; type I>I: invasive-invasive) and coloured according to the class
907 of mutation. (D) Gene maps with type and positions of mutations.

908 **Figure 3 - figure supplement 6.** Gene convergence analysis after removing
909 variants in strains included in Young et al, eLIFE 2017, the largest collection of this
910 analysis (1,078 strains, 105 episodes). Top 20 genes with the most significant

912 mutation enrichment across the entire dataset. (A) Significance of the enrichment for
913 protein-altering mutations. The dashed line depicts the Bonferroni-corrected
914 significance threshold, red circles and blue circles represent genes with p values
915 below and above the Bonferroni threshold, respectively. (B) Enrichment of protein-
916 altering mutations (C) Bar plots of independent mutations separated in 3 panels
917 according to the type of variant (type C>C: colonising-colonising; type C>I:
918 colonising-invasive; type I>I: invasive-invasive) and coloured according to the class
919 of mutation. (D) Gene maps with type and positions of mutations.

920 **Figure 4. Top 20 operons with the most significant mutation enrichment across**
921 **all dataset.** (A) Significance of the enrichment for protein-altering mutations. The
922 dashed line depicts the Bonferroni-corrected significance threshold, red circles and
923 blue circles represent operons with p values below and above the Bonferroni
924 threshold, respectively. (B) Enrichment of protein-altering mutations (C) bar plots of
925 independent mutations separated in 3 panels according to the type of variant (type
926 C>C: colonising-colonising; type C>I: colonising-invasive; type I>I: invasive-invasive)
927 and coloured according to the class of mutation. Mutations were considered
928 independent if they occurred in separate episodes of either colonisation or invasive
929 infection. (D) operon maps with positions of the mutations (relative to the start of the
930 first gene of the operon). Operons are labelled with the names of the genes included,
931 longer labels were shorted for clarity (see Supplementary file 5 for details).

932 **Figure 5.** Modified volcano plot displaying enrichment (x axis) and significance of
933 enrichment (y axis) within type C>C, type C>I and type I>I variants. The horizontal
934 dashed line depicts the Bonferroni-corrected significance threshold and dotted line
935 shows the suggestive significance threshold. Labels indicate genes with significance

936 of enrichment below the suggestive threshold . Genes are coloured in red if the p
937 value is below the Bonferroni-corrected threshold and in blue otherwise.

938 **Figure 5 - figure supplement 1.** Modified volcano plot displaying enrichment (x
939 axis) and significance of enrichment (y axis) for FPR3757 operons across the entire
940 dataset, type CC, type CI and type II variants. The horizontal line depicts the
941 Bonferroni-corrected significance threshold. Genes are coloured in red if the p value
942 is below the Bonferroni-corrected threshold and in blue otherwise. Operons are
943 labelled if they were significantly enriched or reached near significance.

944 **Figure 5 - figure supplement 2.** Gene-set enrichment analysis (GSEA) for protein-
945 modifying mutations in type CC, type CI and type II variants. (A) Gene ontologies
946 (minimum set size 10 for a total of 110 categories) ordered by normalised
947 enrichment score (NES). Ontologies with negative enrichment were excluded. Dark
948 blue bars indicate a significant p value after false discovery rate (FDR) correction (B)
949 Dot plot of 9 significantly enriched ontologies among type II variants.

950 **Figure 6.** Network of mutations co-occurrence. The width and colour of the edges
951 represent the strength of the co-occurrence of mutated genes on the same strain
952 (thin and blue, 2 independent co-occurrences; thick and orange, 3 independent co-
953 occurrences).

954 **Figure 7. Clinical correlates of adaptive signatures within colonising (type**
955 **C>C, panels A-C) and invasive (type I>I, panels D-F) bacterial populations.**
956 Adaptation was inferred by computing the Jaccard index of shared mutated genes
957 between independent episodes, followed by network analysis of infection episodes
958 pairs. The node centrality measure was used as an indicator of adaptation. To avoid
959 overinflation of mutated genes the calculation was limited to the 20 most significantly
960 enriched genes within each group of mutations. (A, D) Density of centrality values

961 across colonisation (panel A) and infection categories (panel D). (B, E) Number and
962 proportion of adaptive episodes. An adaptive episode was defined by a centrality >
963 0. (C, F) Distribution of mutations in the 20 most significantly enriched genes across
964 categories of colonisation (panel C) and infection (panel F).

965 **Figure 7 - figure supplement 1.** Clinical manifestations and infection sites of
966 invasive episodes, grouped by the infection syndromes classification used for the
967 adaptation analysis.

968 **Figure 7 - figure supplement 2.** Network of colonisation/infection episodes for type
969 CC (panel A), type CI (panel B) and type II variants (panel C). Nodes indicate
970 independent episodes, colored based on the clinical syndrome, edges show
971 connections based on shared mutated genes (the width of the connection is
972 proportional to the Jaccard index).

973

974

975 **TABLES**

976 **Table 1.** Microbiological and clinical characteristics of the colonisation and infection
977 episodes included in the within-host evolution analysis

	Strains (n= 2590)	Episodes (n = 396)
Sequence type		
30	342 (13.2%)	43 (10.9%)
22	277 (10.7%)	44 (11.1%)
5	271 (10.5%)	42 (10.6%)
45	198 (7.6%)	38 (9.6%)
15	156 (6.0%)	4 (3.5%)
1	133 (5.1%)	14 (3.5%)
93	110 (4.2%)	29 (7.3%)
8	107 (4.1%)	18 (4.5%)
239	100 (3.9%)	29 (7.3%)
Other	896 (34.6%)	125 (31.6%)
MecA positive	1001 (38.6%)	207 (52.3%)
Infection syndrome		
Skin infection	204 (7.9%)	32 (8.1%)
Osteoarticular infection	77 (3.0%)	17 (4.3%)
Bacteraemia without focus	588 (22.7%)	152 (38.4%)
Bacteraemia with focus	331 (12.8%)	85 (21.5%)
Endocarditis	197 (7.6%)	44 (11.1%)
No invasive strains		66 (16.7%)
Colonisation syndrome		
Nasal carriage	974 (37.6%)	166 (42%)
Cystic fibrosis	57 (2.2%)	9 (2%)

Atopic dermatitis	162 (6.3%)	9 (2%)
No colonising strains		212 (54%)

978

979 **Table 1 – table supplement 1.** List of within-host studies included in the analysis.

980

Author, year	PMID	N independent episodes	N sequences	Ref
Gao W, 2015	28348811	1	18	(23)
Howden BP, 2011	22102812	5	10	(41)
Young BC, 2012	22393007	3	167	(27)
Golubchik, 2013	23658690	13	120	(43)
Burd EM, 2014	24850355	1	3	(44)
Rishishwar L, 2016	27446992	1	3	(33)
Trouillet-Assant S, 2016	26918656	3	6	(29)
Young BC, 2017	29256859	105	1078	(12)
Rouard C, 2018	30275089	1	3	(32)
Langhanki L, 2018	30348081	1	2	(38)
Altman DR, 2018	30061376	10	23	(47)
Giulieri SG, 2018	30103826	49	111	(17)
Benoit JB, 2018	29723202	8	42	(45)
Suligoy CM, 2018	29456969	1	3	(31)
Harkins CP, 2018	28951239	27	248	(42)
Tan X, 2019	30753350	4	8	(30)
Loss G, 2019	31696062	1	2	(36)
Kuroda M, 2019	31474962	1	16	(39)
Azarian T, 2019	31244886	3	44	(46)
Wuethrich D, 2019	30726929	1	5	(28)

Ji S, 2020	32176794	3	20	(40)
Miller CR, 2020	31932377	1	2	(35)
Liu J, 2020	31919223	2	12	(37)
Petrovic Fabijan A, 2020	32066959	12	57	(34)
Tong SYC, 2020	32044943	138	585	(26)

981

982 **Table 2.** Modified McDonald-Kreitman table displaying counts of variants (point
983 mutations and structural variants) and the neutrality index for type C>I and type I>I
984 variants (both compared to type C>C variants).

Classification of variant	Number of variants (Neutrality index)		
	Type C>C	Type C>I	Type I>I
synonymous	381	130	155
non-synonymous	978	300 <i>(0.9)</i>	503 <i>(1.3)*</i>
intergenic	544	197 <i>(1.1)</i>	549 <i>(2.5)**</i>
truncating	197	58 <i>(0.9)</i>	190 <i>(2.4)**</i>
IS insertion	17	6 <i>(1.0)</i>	137 <i>(19.8)**</i>
large deletion	76	17 <i>(0.6)*</i>	122 <i>(3.9)**</i>

985

986 Values are counts of independent mutations. The neutrality index is shown in brackets in italic.

987 Significance testing: *: p < 0.05; ** p < 0.005

988

989 **Table 3. Genome-wide significant gene signatures of within-host evolution.**

990 The genes shown reached genome-wide significance in the entire dataset or in
991 either type C>C, type C>I or type I>I variants.

Gene	p value (whole dataset)	Description	N independent mutations			Significance
			Type C>C	Type C>I	Type I>I	

<i>agrA**</i>	7.04×10^{-28}	accessory gene regulator protein A	5**	9**	8**	Part of the agr quorum sensing system, which is the master regulator of virulence factors expression in <i>S. aureus</i> . Recurrent mutations associated with invasive disease.
<i>agrC**</i>	2.84×10^{-10}	accessory gene regulator protein C	4	2	6**	Histidine kinase, receptor for extracellular autoactivating peptide (AIP). Phosphorylates <i>agrA</i> .
<i>stp1**</i>	1.13×10^{-7}	protein phosphatase 2C domain-containing protein	3	2	3	Associated with vancomycin resistance
<i>mpfR**</i>	4.55×10^{-6}	oxacillin resistance-related FmtC protein	2	0	9**	Main determinant of daptomycin resistance. Association with persistence and immune evasion.
<i>rpoB</i>	7.24×10^{-3}	DNA-directed RNA polymerase subunit beta	1	1	7**	Association with rifampicin resistance, but selection in the absence of rifampicin exposure can happen (R503H). Co-resistance to vancomycin, daptomycin, oxacillin. Association with persistence.

992

** significant enrichment (above the Bonferroni-corrected cut-off, see methods)

993 **Table 3 – table supplement 1. Gene signatures of within-host evolution with**
 994 **suggestive significant enrichment.** The genes shown reached the suggestive
 995 significance threshold in the entire dataset or in either type C>C, type C>I or type I>I
 996 variants.

Gene	p value (whole dataset)	Description	N independent mutations			Significance
			Type C>C	Type C>I	Type I>I	
<i>sucA</i> *	6.82×10^{-5}	2-oxoglutarate dehydrogenase E1 component	6	2	2	Encodes a subunit of the α -ketoglutarate dehydrogenase of the tricarboxylic acid cycle (TCA cycle)
<i>saeR</i> *	1.83×10^{-4}	DNA-binding response regulator SaeR	2	1	2	Regulator component of the saeRS two-component system. Virulence regulation.
<i>accB</i>	4.27×10^{-4}	Biotin carboxyl carrier protein of acetyl-CoA carboxylase	3*	1	0	Part of the fatty acid synthesis pathway of <i>S. aureus</i>
SAUSA300_1856	6.41×10^{-4}	hypothetical protein	4*	0	0	Putative intracellular protease. No data on <i>S. aureus</i>
<i>xpaC</i>	1.38×10^{-3}	hypothetical protein	4*	0	0	Predicted 5-bromo-4-chloroindolyl phosphate hydrolysis protein, no data on <i>S. aureus</i>
<i>rpsJ</i>	1.58×10^{-3}	30S ribosomal protein S10	3*	0	0	Mutations at residues 53-60 are associated with tigecycline resistance, at no apparent fitness cost.
SAUSA300_2399	1.68×10^{-3}	ABC transporter ATP-binding protein	4*	0	0	No data on <i>S. aureus</i>
<i>walR</i>	2.10×10^{-3}	DNA-binding response regulator	1	0	3*	Part of walKR two-component response regulator. Associated with vancomycin resistance.

<i>yjbH</i>	3.55×10^{-3}	Dsba-family protein	1	0	3*	Negative regulator of <i>spx</i> (directs its ClpXP-dependent degradation). Association with antibiotic resistance, virulence regulation and oxidative stress resistance.
<i>purR</i>	3.86×10^{-3}	Pur operon repressor	0	1	3*	<i>purR</i> mutants: increased biofilm formation and virulence in animal model; higher capacity to invade epithelial cells.
<i>era</i>	5.34×10^{-3}	GTP-binding protein Era	0	1	3*	Involved in ribosome assembly and stringent response.
<i>pbp2</i>	7.75×10^{-3}	penicillin binding protein 2	6*	0	0	Role in methicillin resistance (PBP2a synergism). Increased expression after oxacillin exposure.
<i>fakA</i>	9.90×10^{-3}	hypothetical protein	5*	0	0	Fatty acid kinase. Deletion mutant displayed increased virulence in a murine model of skin infection.
<i>sgtB</i>	2.65×10^{-2}	glycosyltransferase	0	0	3*	<i>sgtB</i> mutations in adaptive laboratory evolution experiments upon vancomycin exposure.

997

* suggestive significant enrichment (above the suggestive significance cut-off, see methods)

998

999 **SUPPLEMENTARY FILES**

1000 **Supplementary file 1.** List of colonisation/infection episodes included with
1001 publication data (first author, year, PubMed id), number of strains, sites of collection,
1002 clinical characteristics, classification of colonisation and infection episodes.

1003 **Supplementary file 2.** List of strains included with site and date of collection,
1004 sequence type, presence of the *mecA* gene, information on whether the strain was
1005 designed as internal reference or baseline index strain, mash distance to the internal
1006 reference, number of variants called (as compared to the internal reference),
1007 sequencing metrics.

1008 **Supplementary file 3.** List of variants identified annotated with gene, gene
1009 sequence, FPR3757 homolog, FPR3757 operon. Point mutations, IS insertions,
1010 large deletions and copy number variants are presented separately.

1011 **Supplementary file 4.** Gene enrichment analysis for all mutated genes with a
1012 FPR3757 homolog with number of mutations, gene length, mutation enrichment, p
1013 value based on a Poisson regression to model the number of variants per gene.
1014 Results are presented separately for the complete dataset and for type C>C, type
1015 C>I, and type I>I variants.

1016 **Supplementary file 5.** Operon enrichment analysis for all FPR3757 operons (i.e.
1017 mutated genes that could be assigned to a FPR3757 operon) with number of
1018 mutations, operon length, mutation enrichment, p value based on a Poisson
1019 regression to model the number of variants per operon. Results are presented
1020 separately for the complete dataset and for type C>C, type C>I, and type I>I
1021 variants.

1022 **Supplementary file 6.** Gene set enrichment analysis for mutations in genes
1023 aggregated in gene ontologies (GO) categories with enrichment score, normalised

1024 enrichment score (NES), unadjusted and false-discovery rate (FDR) adjusted p
1025 value. Results are presented separately for the complete dataset and for type C>C,
1026 type C>I, and type I>I variants.

1027

1028

1029 **REFERENCES**

- 1030 1. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG, Jr.
1031 *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical
1032 manifestations, and management. *Clin Microbiol Rev.* 2015;28(3):603-61.
- 1033 2. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh
1034 HA, et al. The role of nasal carriage in *Staphylococcus aureus* infections. *Lancet*
1035 *Infect Dis.* 2005;5(12):751-62.
- 1036 3. Krismer B, Weidenmaier C, Zipperer A, Peschel A. The commensal lifestyle of
1037 *Staphylococcus aureus* and its interactions with the nasal microbiota. *Nat Rev*
1038 *Microbiol.* 2017;15(11):675-87.
- 1039 4. Proctor RA. Immunity to *Staphylococcus aureus*: Implications for Vaccine
1040 Development. *Microbiol Spectr.* 2019;7(4).
- 1041 5. Kuehl R, Morata L, Meylan S, Mensa J, Soriano A. When antibiotics fail: a
1042 clinical and microbiological perspective on antibiotic tolerance and persistence of
1043 *Staphylococcus aureus*. *J Antimicrob Chemother.* 2020;75(5):1071-86.
- 1044 6. Hood MI, Skaar EP. Nutritional immunity: transition metals at the pathogen-
1045 host interface. *Nat Rev Microbiol.* 2012;10(8):525-37.
- 1046 7. Marvig RL, Sommer LM, Molin S, Johansen HK. Convergent evolution and
1047 adaptation of *Pseudomonas aeruginosa* within patients with cystic fibrosis. *Nature*
1048 *Genetics.* 2015;47(1):57-64.
- 1049 8. Kennemann L, Didelot X, Aebischer T, Kuhn S, Drescher B, Droege M, et al.
1050 *Helicobacter pylori* genome evolution during human infection.
1051 *Proceedings of the National Academy of Sciences.* 2011;108:5033-8.
- 1052 9. Lieberman TD, Wilson D, Misra R, Xiong LL, Moodley P, Cohen T, et al.
1053 Genomic diversity in autopsy samples reveals within-host dissemination of HIV-
1054 associated *Mycobacterium tuberculosis*. *Nat Med.* 2016;22(12):1470-4.
- 1055 10. Chaguza C, Senghore M, Bojang E, Gladstone RA, Lo SW, Tientcheu PE, et
1056 al. Within-host microevolution of *Streptococcus pneumoniae* is rapid and adaptive
1057 during natural colonisation. *Nat Commun.* 2020;11(1):3442.
- 1058 11. Paterson GK, Harrison EM, Murray GGR, Welch JJ, Warland JH, Holden
1059 MTG, et al. Capturing the cloud of diversity reveals complexity and heterogeneity of
1060 MRSA carriage, infection and transmission. *Nature Communications.*
1061 2015;6(1):6560.
- 1062 12. Young BC, Wu C-H, Gordon NC, Cole K, Price JR, Liu E, et al. Severe
1063 infections emerge from commensal bacteria by adaptive evolution. *eLife.*
1064 2017;6:e30637.
- 1065 13. Van Tyne D, Manson AL, Huycke MM, Karanicolas J, Earl AM, Gilmore MS.
1066 Impact of antibiotic treatment and host innate immune pressure on enterococcal
1067 adaptation in the human bloodstream. *Sci Transl Med.* 2019;11(487).

1068 14. Lees JA, Kremer PHC, Manso AS, Croucher NJ, Ferwerda B, Serón MV, et
1069 al. Large scale genomic analysis shows no evidence for pathogen adaptation
1070 between the blood and cerebrospinal fluid niches during bacterial meningitis. *Microb*
1071 *Genom.* 2017;3(1):e000103.

1072 15. Giulieri SG, Guerillot R, Kwong JC, Monk IR, Hayes AS, Daniel D, et al. Comprehensive Genomic Investigation of Adaptive Mutations Driving the Low-Level
1073 Oxacillin Resistance Phenotype in *Staphylococcus aureus*. *mBio.* 2020;11(6).

1075 16. Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK. Isolates with low-
1076 level vancomycin resistance associated with persistent methicillin-resistant
1077 *Staphylococcus aureus* bacteremia. *Antimicrob Agents Chemother.*
1078 2006;50(9):3039-47.

1079 17. Giulieri SG, Baines SL, Guerillot R, Seemann T, Gonçalves da Silva A,
1080 Schultz M, et al. Genomic exploration of sequential clinical isolates reveals a
1081 distinctive molecular signature of persistent *Staphylococcus aureus* bacteraemia.
1082 *Genome Medicine.* 2018;10(1):65.

1083 18. Wheatley R, Diaz Caballero J, Kapel N, de Winter FHR, Jangir P, Quinn A, et
1084 al. Rapid evolution and host immunity drive the rise and fall of carbapenem
1085 resistance during an acute *Pseudomonas aeruginosa* infection. *Nature*
1086 *Communications.* 2021;12(1):2460.

1087 19. Klemm EJ, Gkrania-Klotsas E, Hadfield J, Forbester JL, Harris SR, Hale C, et
1088 al. Emergence of host-adapted *Salmonella Enteritidis* through rapid evolution in an
1089 immunocompromised host. *Nature Microbiology.* 2016;1(3):15023.

1090 20. Vargas R, Freschi L, Marin M, Epperson LE, Smith M, Oussenko I, et al. In-
1091 host population dynamics of *Mycobacterium tuberculosis* complex during active
1092 disease. *Elife.* 2021;10.

1093 21. Gatt YE, Margalit H. Common Adaptive Strategies Underlie Within-Host
1094 Evolution of Bacterial Pathogens. *Molecular Biology and Evolution.* 2020.

1095 22. Lees JA, Croucher NJ, Goldblatt D, Nosten F, Parkhill J, Turner C, et al. Genome-wide identification of lineage and locus specific variation associated with
1096 pneumococcal carriage duration. *Elife.* 2017;6.

1098 23. Gao W, Monk IR, Tobias NJ, Gladman SL, Seemann T, Stinear TP, et al. Large tandem chromosome expansions facilitate niche adaptation during persistent
1099 infection with drug-resistant *Staphylococcus aureus*. *Microb Genom.*
1100 2015;1(2):e000026.

1102 24. Khademi SMH, Sazinas P, Jelsbak L. Within-Host Adaptation Mediated by
1103 Intergenic Evolution in *Pseudomonas aeruginosa*. *Genome Biology and Evolution.*
1104 2019;11(5):1385-97.

1105 25. Long DR, Wolter DJ, Lee M, Precit M, McLean K, Holmes E, et al. Polyclonality, Shared Strains, and Convergent Evolution in Chronic CF *S. aureus*
1106 Airway Infection. *Am J Respir Crit Care Med.* 2020.

1108 26. Tong SYC, Lye DC, Yahav D, Sud A, Robinson JO, Nelson J, et al. Effect of
1109 Vancomycin or Daptomycin With vs Without an Antistaphylococcal β -Lactam on
1110 Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA
1111 Bacteremia: A Randomized Clinical Trial. *JAMA.* 2020;323(6):527-37.

1112 27. Young BC, Golubchik T, Batty EM, Fung R, Larner-Svensson H, Votintseva
1113 AA, et al. Evolutionary dynamics of *Staphylococcus aureus* during progression from
1114 carriage to disease. *Proc Natl Acad Sci U S A.* 2012;109(12):4550-5.

1115 28. Wuthrich D, Cuenod A, Hinic V, Morgenstern M, Khanna N, Egli A, et al. Genomic characterization of inpatient evolution of MRSA resistant to daptomycin,
1116 vancomycin and ceftaroline. *J Antimicrob Chemother.* 2019;74(5):1452-4.

1118 29. Trouillet-Assant S, Lelievre L, Martins-Simoes P, Gonzaga L, Tasse J, Valour
1119 F, et al. Adaptive processes of *Staphylococcus aureus* isolates during the
1120 progression from acute to chronic bone and joint infections in patients. *Cell Microbiol.*
1121 2016;18(10):1405-14.

1122 30. Tan X, Coureuil M, Ramond E, Euphrasie D, Dupuis M, Tros F, et al. Chronic
1123 *Staphylococcus aureus* Lung Infection Correlates With Proteogenomic and Metabolic
1124 Adaptations Leading to an Increased Intracellular Persistence. *Clin Infect Dis.*
1125 2019;69(11):1937-45.

1126 31. Suligoy CM, Lattar SM, Noto Llana M, Gonzalez CD, Alvarez LP, Robinson
1127 DA, et al. Mutation of *Agr* Is Associated with the Adaptation of *Staphylococcus*
1128 *aureus* to the Host during Chronic Osteomyelitis. *Front Cell Infect Microbiol.*
1129 2018;8:18.

1130 32. Rouard C, Garnier F, Leraut J, Lepainteur M, Rahajamananav L, Languepin J,
1131 et al. Emergence and Within-Host Genetic Evolution of Methicillin-Resistant
1132 *Staphylococcus aureus* Resistant to Linezolid in a Cystic Fibrosis Patient. *Antimicrob
1133 Agents Chemother.* 2018;62(12).

1134 33. Rishishwar L, Kraft CS, Jordan IK. Population Genomics of Reduced
1135 Vancomycin Susceptibility in *Staphylococcus aureus*. *mSphere.* 2016;1(4).

1136 34. Petrovic Fabijan A, Lin RCY, Ho J, Maddocks S, Ben Zakour NL, Iredell JR, et
1137 al. Safety of bacteriophage therapy in severe *Staphylococcus aureus* infection. *Nat
1138 Microbiol.* 2020;5(3):465-72.

1139 35. Miller CR, Dey S, Smolenski PD, Kulkarni PS, Monk JM, Szubin R, et al.
1140 Distinct Subpopulations of Intravalvular Methicillin-Resistant *Staphylococcus aureus*
1141 with Variable Susceptibility to Daptomycin in Tricuspid Valve Endocarditis.
1142 *Antimicrob Agents Chemother.* 2020;64(3).

1143 36. Loss G, Simoes PM, Valour F, Cortes MF, Gonzaga L, Bergot M, et al.
1144 *Staphylococcus aureus* Small Colony Variants (SCVs): News From a Chronic
1145 Prosthetic Joint Infection. *Front Cell Infect Microbiol.* 2019;9:363.

1146 37. Liu J, Gefen O, Ronin I, Bar-Meir M, Balaban NQ. Effect of tolerance on the
1147 evolution of antibiotic resistance under drug combinations. *Science.*
1148 2020;367(6474):200-4.

1149 38. Langhanki L, Berger P, Treffon J, Catania F, Kahl BC, Mellmann A. In vivo
1150 competition and horizontal gene transfer among distinct *Staphylococcus aureus*
1151 lineages as major drivers for adaptational changes during long-term persistence in
1152 humans. *BMC Microbiol.* 2018;18(1):152.

1153 39. Kuroda M, Sekizuka T, Matsui H, Ohsuga J, Ohshima T, Hanaki H. IS256-
1154 Mediated Overexpression of the WalKR Two-Component System Regulon
1155 Contributes to Reduced Vancomycin Susceptibility in a *Staphylococcus aureus*
1156 Clinical Isolate. *Front Microbiol.* 2019;10:1882.

1157 40. Ji S, Jiang S, Wei X, Sun L, Wang H, Zhao F, et al. In-Host Evolution of
1158 Daptomycin Resistance and Heteroresistance in Methicillin-Resistant
1159 *Staphylococcus aureus* Strains From Three Endocarditis Patients. *J Infect Dis.*
1160 2020;221(Suppl 2):S243-S52.

1161 41. Howden BP, McEvoy CR, Allen DL, Chua K, Gao W, Harrison PF, et al.
1162 Evolution of multidrug resistance during *Staphylococcus aureus* infection involves
1163 mutation of the essential two component regulator WalKR. *PLoS Pathog.*
1164 2011;7(11):e1002359.

1165 42. Harkins CP, Pettigrew KA, Oravcova K, Gardner J, Hearn RMR, Rice D, et al.
1166 The Microevolution and Epidemiology of *Staphylococcus aureus* Colonization during
1167 Atopic Eczema Disease Flare. *J Invest Dermatol.* 2018;138(2):336-43.

1168 43. Golubchik T, Batty EM, Miller RR, Farr H, Young BC, Larner-Svensson H, et
1169 al. Within-host evolution of *Staphylococcus aureus* during asymptomatic carriage.
1170 *PLoS One.* 2013;8(5):e61319.

1171 44. Burd EM, Alam MT, Passalacqua KD, Kalokhe AS, Eaton ME, Satola SW, et
1172 al. Development of oxacillin resistance in a patient with recurrent *Staphylococcus*
1173 *aureus* bacteremia. *J Clin Microbiol.* 2014;52(8):3114-7.

1174 45. Benoit JB, Frank DN, Bessesen MT. Genomic evolution of *Staphylococcus*
1175 *aureus* isolates colonizing the nares and progressing to bacteremia. *PLoS One.*
1176 2018;13(5):e0195860.

1177 46. Azarian T, Ridgway JP, Yin Z, David MZ. Long-Term Intrahost Evolution of
1178 Methicillin Resistant *Staphylococcus aureus* Among Cystic Fibrosis Patients With
1179 Respiratory Carriage. *Front Genet.* 2019;10:546.

1180 47. Altman DR, Sullivan MJ, Chacko KI, Balasubramanian D, Pak TR, Sause WE,
1181 et al. Genome Plasticity of agr-Defective *Staphylococcus aureus* during Clinical
1182 Infection. *Infect Immun.* 2018;86(10).

1183 48. Hawkey J, Monk JM, Billman-Jacobe H, Palsson B, Holt KE. Impact of
1184 insertion sequences on convergent evolution of *Shigella* species. *PLoS Genet.*
1185 2020;16(7):e1008931.

1186 49. Toft C, Andersson SG. Evolutionary microbial genomics: insights into bacterial
1187 host adaptation. *Nat Rev Genet.* 2010;11(7):465-75.

1188 50. McEvoy CR, Tsuji B, Gao W, Seemann T, Porter JL, Doig K, et al. Decreased
1189 vancomycin susceptibility in *Staphylococcus aureus* caused by IS256 tempering of
1190 WalKR expression. *Antimicrob Agents Chemother.* 2013;57(7):3240-9.

1191 51. Schreiber F, Szekat C, Josten M, Sahl HG, Bierbaum G. Antibiotic-induced
1192 autoactivation of IS256 in *Staphylococcus aureus*. *Antimicrob Agents Chemother.*
1193 2013;57(12):6381-4.

1194 52. Smyth DS, Kafer JM, Wasserman GA, Velickovic L, Mathema B, Holzman
1195 RS, et al. Nasal carriage as a source of agr-defective *Staphylococcus aureus*
1196 bacteremia. *J Infect Dis.* 2012;206(8):1168-77.

1197 53. Wang Y, Bojer MS, George SE, Wang Z, Jensen PR, Wolz C, et al.
1198 Inactivation of TCA cycle enhances *Staphylococcus aureus* persister cell formation
1199 in stationary phase. *Sci Rep.* 2018;8(1):10849.

1200 54. Lopatkin AJ, Bening SC, Manson AL, Stokes JM, Kohanski MA, Badran AH,
1201 et al. Clinically relevant mutations in core metabolic genes confer antibiotic
1202 resistance. *Science.* 2021;371(6531):eaba0862.

1203 55. Phaneuf PV, Yurkovich JT, Heckmann D, Wu M, Sandberg TE, King ZA, et al.
1204 Causal mutations from adaptive laboratory evolution are outlined by multiple scales
1205 of genome annotations and condition-specificity. *BMC Genomics.* 2020;21(1):514.

1206 56. Mäder U, Nicolas P, Depke M, Pané-Farré J, Debarbouille M, van der Kooi-
1207 Pol MM, et al. *Staphylococcus aureus* Transcriptome Architecture: From Laboratory
1208 to Infection-Mimicking Conditions. *PLoS genetics.* 2016;12(4):e1005962-e.

1209 57. Prados J, Linder P, Redder P. TSS-EMOTE, a refined protocol for a more
1210 complete and less biased global mapping of transcription start sites in bacterial
1211 pathogens. *BMC Genomics.* 2016;17(1):849.

1212 58. Both A, Huang J, Qi M, Lausmann C, Weißelberg S, Büttner H, et al. Distinct
1213 clonal lineages and within-host diversification shape invasive *Staphylococcus*
1214 *epidermidis* populations. *PLOS Pathogens.* 2021;17(2):e1009304.

1215 59. Suligoy CM, Díaz RE, Gehrke AK, Ring N, Yebra G, Alves J, et al. Acapsular
1216 *Staphylococcus aureus* with a non-functional agr regains capsule expression after

1217 passage through the bloodstream in a bacteremia mouse model. *Sci Rep.*
1218 2020;10(1):14108.

1219 60. Machado H, Seif Y, Sakoulas G, Olson CA, Hefner Y, Anand A, et al.
1220 Environmental conditions dictate differential evolution of vancomycin resistance in
1221 *Staphylococcus aureus*. *Communications Biology*. 2021;4(1):793.

1222 61. Guerillot R, Goncalves da Silva A, Monk I, Giulieri S, Tomita T, Alison E, et al.
1223 Convergent Evolution Driven by Rifampin Exacerbates the Global Burden of Drug-
1224 Resistant *Staphylococcus aureus*. *mSphere*. 2018;3(1).

1225 62. Austin CM, Garabaglu S, Krute CN, Ridder MJ, Seawell NA, Markiewicz MA,
1226 et al. Contribution of YjbH to Virulence Factor Expression and Host Colonization in
1227 Staphylococcus aureus. *Infection and Immunity*. 2019;87(6):e00155-19.

1228 63. Göhring N, Fedtke I, Xia G, Jorge AM, Pinho MG, Bertsche U, et al. New role
1229 of the disulfide stress effector YjbH in β -lactam susceptibility of *Staphylococcus*
1230 *aureus*. *Antimicrob Agents Chemother*. 2011;55(12):5452-8.

1231 64. Renzoni A, Andrey DO, Jousselin A, Barras C, Monod A, Vaudaux P, et al.
1232 Whole genome sequencing and complete genetic analysis reveals novel pathways to
1233 glycopeptide resistance in *Staphylococcus aureus*. *PLoS One*. 2011;6(6):e21577.

1234 65. Engman J, Rogstam A, Frees D, Ingmer H, von Wachenfeldt C. The YjbH
1235 adaptor protein enhances proteolysis of the transcriptional regulator Spx in
1236 *Staphylococcus aureus*. *J Bacteriol*. 2012;194(5):1186-94.

1237 66. Paudel A, Panthee S, Hamamoto H, Grunert T, Sekimizu K. YjbH regulates
1238 virulence genes expression and oxidative stress resistance in *Staphylococcus*
1239 *aureus*. *Virulence*. 2021;12(1):470-80.

1240 67. Sause WE, Balasubramanian D, Irnov I, Copin R, Sullivan MJ, Sommerfield
1241 A, et al. The purine biosynthesis regulator PurR moonlights as a virulence regulator
1242 in *Staphylococcus aureus*. *Proc Natl Acad Sci U S A*. 2019;116(27):13563-72.

1243 68. Goncheva MI, Flannagan RS, Sterling BE, Laakso HA, Friedrich NC, Kaiser
1244 JC, et al. Stress-induced inactivation of the *Staphylococcus aureus* purine
1245 biosynthesis repressor leads to hypervirulence. *Nat Commun*. 2019;10(1):775.

1246 69. Goncheva MI, Flannagan RS, Heinrichs DE. De Novo Purine Biosynthesis Is
1247 Required for Intracellular Growth of *Staphylococcus aureus* and for the
1248 Hypervirulence Phenotype of a purR Mutant. *Infect Immun*. 2020;88(5).

1249 70. Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, et al.
1250 Validating the AMRFinder Tool and Resistance Gene Database by Using
1251 Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of
1252 Isolates. *Antimicrob Agents Chemother*. 2019;63(11).

1253 71. Levin-Reisman I, Brauner A, Ronin I, Balaban NQ. Epistasis between
1254 antibiotic tolerance, persistence, and resistance mutations. *Proc Natl Acad Sci U S*
1255 *A*. 2019;116(29):14734-9.

1256 72. Skwark MJ, Croucher NJ, Puranen S, Chewapreecha C, Pesonen M, Xu YY,
1257 et al. Interacting networks of resistance, virulence and core machinery genes
1258 identified by genome-wide epistasis analysis. *PLoS Genet*. 2017;13(2):e1006508.

1259 73. Wadsworth CB, Arnold BJ, Sater MRA, Grad YH. Azithromycin Resistance
1260 through Interspecific Acquisition of an Epistasis-Dependent Efflux Pump Component
1261 and Transcriptional Regulator in *Neisseria gonorrhoeae*. *mBio*. 2018;9(4).

1262 74. Yokoyama M, Stevens E, Laabei M, Bacon L, Heesom K, Bayliss S, et al.
1263 Epistasis analysis uncovers hidden antibiotic resistance-associated fitness costs
1264 hampering the evolution of MRSA. *Genome Biology*. 2018;19(1):94.

1265 75. Phillips PC. Epistasis — the essential role of gene interactions in the structure
1266 and evolution of genetic systems. *Nature Reviews Genetics*. 2008;9(11):855-67.

1267 76. Aseev LV, Boni IV. Extraribosomal functions of bacterial ribosomal proteins.
1268 Molecular Biology. 2011;45(5):739.

1269 77. Monk IR, Shaikh N, Begg SL, Gajdiss M, Sharkey LKR, Lee JYH, et al. Zinc-
1270 binding to the cytoplasmic PAS domain regulates the essential WalK histidine kinase
1271 of *Staphylococcus aureus*. Nature Communications. 2019;10(1):3067.

1272 78. Cameron DR, Ward DV, Kostoulias X, Howden BP, Moellering RC, Jr.,
1273 Eliopoulos GM, et al. Serine/threonine phosphatase Stp1 contributes to reduced
1274 susceptibility to vancomycin and virulence in *Staphylococcus aureus*. J Infect Dis.
1275 2012;205(11):1677-87.

1276 79. Trong HNG, Prunier A-L, Leclercq R. Hypermutable and fluoroquinolone-
1277 resistant clinical isolates of *Staphylococcus aureus*. Antimicrobial agents and
1278 chemotherapy. 2005;49(5):2098-101.

1279 80. Wheeler NE, Gardner PP, Barquist L. Machine learning identifies signatures
1280 of host adaptation in the bacterial pathogen *Salmonella enterica*. PLoS Genet.
1281 2018;14(5):e1007333.

1282 81. Bailey SF, Blanquart F, Bataillon T, Kassen R. What drives parallel
1283 evolution?: How population size and mutational variation contribute to repeated
1284 evolution. Bioessays. 2017;39(1):1-9.

1285 82. Bryant JM, Brown KP, Burbaud S, Everall I, Belardinelli JM, Rodriguez-Rincon
1286 D, et al. Stepwise pathogenic evolution of *Mycobacterium abscessus*. Science.
1287 2021;372(6541).

1288 83. Key FM, Khadka VD, Romo-González C, Blake KJ, Deng L, Lynn TC, et al.
1289 On-person adaptive evolution of *Staphylococcus aureus* during atopic
1290 dermatitis increases disease severity. bioRxiv. 2021:2021.03.24.436824.

1291 84. Didelot X, Walker AS, Peto TE, Crook DW, Wilson DJ. Within-host evolution
1292 of bacterial pathogens. Nat Rev Microbiol. 2016;14(3):150-62.

1293 85. McVicker G, Prajsnar TK, Williams A, Wagner NL, Boots M, Renshaw SA, et
1294 al. Clonal expansion during *Staphylococcus aureus* infection dynamics reveals the
1295 effect of antibiotic intervention. PLoS Pathog. 2014;10(2):e1003959.

1296 86. Guerillot R, Li L, Baines S, Howden B, Schultz MB, Seemann T, et al.
1297 Comprehensive antibiotic-linked mutation assessment by resistance mutation
1298 sequencing (RM-seq). Genome Med. 2018;10(1):63.

1299 87. Peleg AY, Miyakis S, Ward DV, Earl AM, Rubio A, Cameron DR, et al. Whole
1300 genome characterization of the mechanisms of daptomycin resistance in clinical and
1301 laboratory derived isolates of *Staphylococcus aureus*. PLoS One. 2012;7(1):e28316.

1302 88. Jiang JH, Dexter C, Cameron DR, Monk IR, Baines SL, Abbott IJ, et al.
1303 Evolution of Daptomycin Resistance in Coagulase-Negative Staphylococci Involves
1304 Mutations of the Essential Two-Component Regulator WalKR. Antimicrob Agents
1305 Chemother. 2019;63(3).

1306 89. Guerillot R, Kostoulias X, Donovan L, Li L, Carter GP, Hachani A, et al.
1307 Unstable chromosome rearrangements in *Staphylococcus aureus* cause phenotype
1308 switching associated with persistent infections. Proc Natl Acad Sci U S A.
1309 2019;116(40):20135-40.

1310 90. Laabei M, Uhlemann AC, Lowy FD, Austin ED, Yokoyama M, Ouadi K, et al.
1311 Evolutionary Trade-Offs Underlie the Multi-faceted Virulence of *Staphylococcus*
1312 *aureus*. PLoS Biol. 2015;13(9):e1002229.

1313 91. Stinear TP, Seemann T, Pidot S, Frigui W, Reysset G, Garnier T, et al.
1314 Reductive evolution and niche adaptation inferred from the genome of
1315 *Mycobacterium ulcerans*, the causative agent of Buruli ulcer. Genome Res.
1316 2007;17(2):192-200.

1317 92. Batut B, Knibbe C, Marais G, Daubin V. Reductive genome evolution at both
1318 ends of the bacterial population size spectrum. *Nat Rev Microbiol.* 2014;12(12):841-
1319 50.

1320 93. Thwaites GE, Gant V. Are bloodstream leukocytes Trojan Horses for the
1321 metastasis of *Staphylococcus aureus*? *Nat Rev Microbiol.* 2011;9(3):215-22.

1322 94. Surewaard BG, Deniset JF, Zemp FJ, Amrein M, Otto M, Conly J, et al.
1323 Identification and treatment of the *Staphylococcus aureus* reservoir in vivo. *J Exp
1324 Med.* 2016;213(7):1141-51.

1325 95. Basuino L, Jousselin A, Alexander JAN, Strynadka NCJ, Pinho MG,
1326 Chambers HF, et al. PBP4 activity and its overexpression are necessary for PBP4-
1327 mediated high-level β -lactam resistance. *J Antimicrob Chemother.* 2018;73(5):1177-
1328 80.

1329 96. Gao W, Cameron DR, Davies JK, Kostoulias X, Stepnell J, Tuck KL, et al. The
1330 RpoB H(4)(8)(1)Y rifampicin resistance mutation and an active stringent response
1331 reduce virulence and increase resistance to innate immune responses in
1332 *Staphylococcus aureus*. *J Infect Dis.* 2013;207(6):929-39.

1333 97. Novick RP, Geisinger E. Quorum sensing in staphylococci. *Annu Rev Genet.*
1334 2008;42:541-64.

1335 98. Shopsin B, Drlica-Wagner A, Mathema B, Adhikari RP, Kreiswirth BN, Novick
1336 RP. Prevalence of agr dysfunction among colonizing *Staphylococcus aureus* strains.
1337 *J Infect Dis.* 2008;198(8):1171-4.

1338 99. Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R,
1339 et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. *Nature.*
1340 2017;545(7655):446-51.

1341 100. Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2.
1342 *Genome Biology.* 2019;20(1):257.

1343 101. Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics.*
1344 2014;30(14):2068-9.

1345 102. Lemoine F, Gascuel O. Gotree/Goalign : Toolkit and Go API to facilitate the
1346 development of phylogenetic workflows. *bioRxiv.* 2021:2021.06.09.447704.

1347 103. Page AJ, Taylor B, Delaney AJ, Soares J, Seemann T, Keane JA, et al. SNP-
1348 sites: rapid efficient extraction of SNPs from multi-FASTA alignments. *Microbial
1349 Genomics.* 2016;2(4).

1350 104. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von
1351 Haeseler A, et al. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic
1352 Inference in the Genomic Era. *Molecular Biology and Evolution.* 2020;37(5):1530-4.

1353 105. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing
1354 genomic features. *Bioinformatics.* 2010;26(6):841-2.

1355 106. Brynildsrud O, Snipen LG, Bohlin J. CNOGpro: detection and quantification of
1356 CNVs in prokaryotic whole-genome sequencing data. *Bioinformatics.*
1357 2015;31(11):1708-15.

1358 107. Fuchs S, Mehlan H, Bernhardt J, Hennig A, Michalik S, Surmann K, et al.
1359 AureoWiki- The repository of the *Staphylococcus aureus* research and annotation
1360 community. *International Journal of Medical Microbiology.* 2018;308(6):558-68.

1361 108. Dehal PS, Joachimiak MP, Price MN, Bates JT, Baumohl JK, Chivian D, et al.
1362 MicrobesOnline: an integrated portal for comparative and functional genomics.
1363 *Nucleic Acids Res.* 2010;38(Database issue):D396-400.

1364 109. Stoletzki N, Eyre-Walker A. Estimation of the Neutrality Index. *Molecular
1365 Biology and Evolution.* 2010;28(1):63-70.






1366 110. Martincorena I, Raine KM, Gerstung M, Dawson KJ, Haase K, Van Loo P, et
1367 al. Universal Patterns of Selection in Cancer and Somatic Tissues. *Cell*.
1368 2017;171(5):1029-41.e21.
1369 111. Törönen P, Medlar A, Holm L. PANNZER2: a rapid functional annotation web
1370 server. *Nucleic Acids Res*. 2018;46(W1):W84-w8.
1371 112. clusterProfiler: an R Package for Comparing Biological Themes Among Gene
1372 Clusters. *OMICS: A Journal of Integrative Biology*. 2012;16(5):284-7.
1373 113. Griffith DM, Veech JA, Marsh CJ. cooccur: Probabilistic Species Co-
1374 Occurrence Analysis in R. 2016. 2016;69(Code Snippet 2):17.
1375




1376 **ACKNOWLEDGMENTS**


1377 The authors declare that they have no competing interests. All data needed to
1378 evaluate the conclusions in the paper are present in the paper and/or the
1379 Supplementary Materials. This work was supported by a Research Fellowship to
1380 BPH and TPS from the National Health and Medical Research Council, Australia.
1381 SGG was supported by a PhD scholarship of the University of Melbourne. We
1382 acknowledge the CAMERA2 investigators and trial steering committee for sharing
1383 sequences and clinical metadata of trial participants with multiple sequential
1384 bacteraemia strains.



1385

1386
1387


A*New host***B****C****Gene ontologies****Coding regions****Intergenic regions****Operons****D**



A**B****C**




A**B**


N independent insertions




A**B****C**

agrA**Mutation**


- Q46*
- I75N
- T88M
- L131fs
- Ter133Lext*?
- D137fs
- Ter141fs
- G148D
- I150fs
- L162fs
- E163fs
- E163Y
- H174fs
- L186F
- F197fs
- R195C
- H208fs
- R218*
- R218C
- E226fs
- I238fs
- Y238Y

agrC**Mutation**


- D2fs
- I30fs
- L38fs
- F117L
- F117LI139fs
- S28TI297V
- Y168fs
- IS insertion (intragenic)
- Q175E
- L193*
- K206fs

stp1**Mutation**


- D9V
- Q70R
- N93_K111del
- S136fs
- N137D
- V247L

mpRF**Mutation**


- L78F
- S295A
- S295L
- P314L
- S337L
- I348del
- W424C
- L451_V452delinsF
- T472K
- E593D
- L776S
- L826F

sucA**Mutation**


- V42I
- H242Q
- V425D
- I500M
- P562T
- S622G
- S691P
- P717H
- P717T
- D897fs
- P909L

saeR**Mutation**


- V49_M53del
- P74S
- A165D
- E179K
- A190T

accB**Mutation**


- V53A
- A70T
- T112I
- I134V

SAUSA300_1856**Mutation**




- I32T
- G85A
- R86*
- D157Y


xpaC**Mutation**


- I31V
- Y132fs
- D179N




SAUSA300_1613**Mutation**




- I92M
- L162F
- D171N
- I196T
- Ter356Yext*?

A**B****C**





A**B****C**

A**B****C****Enrichment**




- 10
- 20
- 40

Mutation

- truncating
- non-synonymous
- IS insertion (intragenic)

Independent acquisitions

- ▲ 1
- ▲ 2
- ▲ 3

A**B****C****Enrichment**

- 5
- 10




Mutation

- truncating
- non-synonymous
- intergenic
- IS (intergenic)
- IS (intragenic)




Independent acquisitions



- ▲ 1
- ▲ 2
- ▲ 3


$-\log_{10}(p \text{ value})$



$-\log_{10}(p \text{ value})$




A**B**




A


bioRxiv preprint doi: <https://doi.org/10.1101/2022.02.11.480068>; this version posted February 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.




C




B




D



E




F




Infection episode



Adaption network of type II variants



Adaptation network of type CC variants



Adaptation network of type CI variants

